

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## A Study Protocol for a Randomised Controlled Trial Evaluating the Benefits from Bimodal Solution with Cochlear Implant and Hearing Aid vs. Bilateral Hearing Aids in Patients with Asymmetric Speech Identification Scores.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-070296
Article Type:	Protocol
Date Submitted by the Author:	18-Nov-2022
Complete List of Authors:	Jakobsen, Yeliz; Odense University Hospital, Head & Neck Surgery and Audiology; Odense University Hospital Christensen Andersen, Lou-Ann; Vejle Hospital, Department of Ophthalmology Schmidt, Jesper; Odense University Hospital, Department of Audiology; Odense University Hospital, Department of Oto-Rhino-Laryngology
Keywords:	Audiology < OTOLARYNGOLOGY, Speech pathology < OTOLARYNGOLOGY, Adult otolaryngology < OTOLARYNGOLOGY

SCHOLARONE™  
Manuscripts

# A Study Protocol for a Randomised Controlled Trial Evaluating the Benefits from Bimodal Solution with Cochlear Implant and Hearing Aid vs. Bilateral Hearing Aids in Patients with Asymmetric Speech Identification Scores.

Yeliz Jakobsen<sup>1,2\*</sup>, Lou-Ann Christensen Andersen<sup>3</sup>, Jesper Hvass Schmidt<sup>1,2</sup>

## Affiliation

<sup>1</sup> Research Unit for ORL – Head & Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark; University of Southern Denmark, Odense, Denmark

<sup>2</sup> OPEN, Odense Patient data Explorative Network, Odense University Hospital, Odense, Denmark.

<sup>3</sup>Department of Ophthalmology, Lillebaelt Hospital, Vejle Hospital.

\*Correspondence to Dr. Yeliz Jakobsen; [Yeliz.jakobsen@rsyd.dk](mailto:Yeliz.jakobsen@rsyd.dk)

Date: Sunday, 21<sup>st</sup> August 2022

Version: 3

## Abstract

### Introduction

Cochlear implant (CI) and hearing aid (HA) in a bimodal solution (CI + HA) is compared to bilateral HAs (HA +HA) to test if the bimodal solution result in better speech intelligibility and self-reported quality of life.

### Methods and Analysis

This randomised controlled trial (RCT) is conducted in Odense University Hospital, Denmark.

Sixty adult bilateral HA users referred for CI surgery is enrolled if eligible and undergo:

audiometry, speech perception in noise (HINT: Hearing in Noise Test), Speech Identification

Scores (SIS) and video head impulse test (v-HIT). All participants will receive new

replacement HAs. After one month they will be randomly assigned (1:1) to the intervention

group (CI+HA) or to the delayed intervention control group (HA+HA). The intervention group

(CI+HA) will receive a CI on the ear with a poorer speech recognition score and continue

1  
2  
3  
4 32 using the HA on the other ear. The control group (HA+HA) will receive a CI after a total of 4  
5  
6  
7 33 months of bilateral HA use.  
8  
9 34 The primary outcome measures are Speech intelligibility measured objectively with HINT  
10  
11 35 (sentences in noise) and DANTALE I (words) and subjectively with the Speech, Spatial and  
12  
13 36 Qualities of Hearing scale questionnaire (SSQ-12). Secondary outcomes are patient reported  
14  
15  
16 37 Health-Related Quality of Life (HRQoL) scores assessed with the Nijmegen Cochlear Implant  
17  
18 38 Questionnaire (NCIQ), the Tinnitus Handicap Inventory (THI) and Dizziness Handicap  
19  
20 39 Inventory (DHI). Third outcome is listening effort assessed with pupil dilation during HINT  
21  
22  
23 40 In conclusion, the purpose is to improve clinical decision-making for CI candidacy and  
24  
25 41 optimize bimodal solutions.  
26  
27  
28 42

## 30 43 Ethics and Dissemination

31  
32  
33 44 This study protocol was approved by the Ethics Committee Southern Denmark project ID S-  
34  
35 45 20200074G. All participants are required to sign an informed consent form.  
36  
37 46 This study will be published upon completion in a peer-reviewed publications and scientific  
38  
39  
40 47 conferences.  
41  
42 48

43  
44  
45 49 Trial Registration Number: NCT04919928 (ClinicalTrials.gov)  
46  
47 50  
48  
49 51  
50  
51 52  
52  
53 53  
54  
55 54  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 55 **Strengths and Limitations of This Study**

- The study uses comprehensive measures of self-reported outcomes as well as objective tests of speech intelligibility.
- Listening effort controlled with pupillometry during objective tests of speech intelligibility.
- Open label RCT (blinding is not possible due to visibility of the CI).
- Possible large drop rates if new HAs improve speech intelligibility to an extent that CI treatment is rejected or postponed.

## 64 **Introduction**

### 65 **Background**

66 Cochlear implants (CIs) have been used to restore hearing in individuals with severe to  
67 profound sensorineural hearing loss. Initially, most patients receiving a cochlear implant were  
68 profoundly deaf in both ears. (1, 2) However, recently it has become more common to implant  
69 patients with significant residual hearing in the affected ear, as well as in patients with  
70 asymmetric hearing loss and single-sided deafness, with significant residual hearing or normal  
71 hearing on the contralateral side.(3, 4) A CI in one ear and a HA in the other ear can provide  
72 enhanced hearing performance in patients with asymmetrical hearing.(5, 6) The combination  
73 of CI and HA is referred to as bimodal hearing or bimodal solution.(7)

### 75 **CI Candidacy**

76 In the UK, The National Institute for Health and Care Excellence (NICE) have listed guidelines  
77 for cochlear implantation and recommends that unilateral CI is offered to patients with severe

1  
2  
3  
4 78 to profound deafness who do not receive adequate benefit from acoustic hearing aids. Severe  
5  
6 79 to profound deafness is defined as pure-tone audiometric threshold  $\geq 80$  dB HL at 2 or more  
7  
8  
9 80 frequencies (500 Hz, 1,000 Hz, 2,000 Hz, 3,000 Hz and 4,000 Hz). Another criteria is that SIS<  
10  
11 81 50% in the ear considered for implantation and in best aided condition SIS $\leq$ 60%(8).

12  
13 82 The Danish CI candidacy criteria consists of SIS (without HAs, measured with headphones)  
14  
15  
16 83  $\leq$ 45% and a SIS  $\leq$ 65% (in best aided condition) in the ear considered for implantation using  
17  
18 84 DANTALE I monosyllabic word-lists.(9) Additional testing to evaluate speech understanding  
19  
20 85 is assessed by HINT.(10, 11)

21  
22  
23 86 The recommendation for a CI might be less clear for patients with asymmetric hearing  
24  
25 87 because they may not fall into the traditional referral criteria but would likely benefit from a  
26  
27  
28 88 CI. It is therefore necessary to establish more evidence to support the effectiveness of bimodal  
29  
30 89 CI+HA versus HAs in patients with asymmetric hearing.

31  
32 90  
33  
34

### 35 91 Bimodal Solution vs. Bilateral HAs

36  
37 92 Normal hearing listeners (NH) benefit from listening with two ears, which help them  
38  
39  
40 93 understand speech in noise and identify sound location.

41  
42 94 Benefits from listening with two ears include: head shadow effect, binaural summation,  
43  
44 95 binaural squelch, localization and spatial release from masking.(12-15)

45  
46 96 Patients with hearing loss often do not have these benefits, and they are often not accessible to  
47  
48  
49 97 CI patients. (15)Many bimodal CI and HA users are missing these benefits because the devices  
50  
51 98 are unsynchronized.(16)

52  
53  
54 99 Until now it is unknown when to introduce the bimodal solution and making sure that  
55  
56 100 patients are well-fitted with hearing aids when they are given the candidacy assessment.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

101 The question is if the bimodal benefits are bigger than the bilateral hearing aid condition  
102 when they are well fitted?

103 This study will therefore support and strengthen the preoperative clinical decision to  
104 recommend a bimodal solution with a CI and a HA versus the continuous use of bilateral HAs.  
105 This may offer the patient faster and more effective treatment because delaying the surgery  
106 may not be beneficial.

## 108 Patient-Reported Outcome Measures

109 Benefits of the CI are measured subjectively with Patient-Reported Outcome Measures  
110 (PROMs) as SSQ12, NCIQ, THI and DHI.(17-24)

111  
112 The validity and reproducibility of the Danish version of THI has been reported(24). SSQ12,  
113 DHI, NCIQ have all been translated into Danish and backward translated to English following a  
114 cultural adaption and pilot-testing to ensure correct understanding of the questionnaires.  
115 Test-retest reliability has been assessed as well.(18, 20, 22)

## 117 Listening Effort

118 Patients with CI often experience high levels of listening effort, they often report that  
119 understanding speech causes high levels of increased sustained effort which results in  
120 feelings of fatigue.(25) These feelings may lead patients to withdraw socially due to the  
121 stresses involved in communication even though they may not specifically report difficulties  
122 with speech understanding.(19)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

123 Effort in listeners with NH can be reflected by the relationship between speech intelligibility  
124 and pupil-dilation.(26) Listening effort has been defined as the “Deliberate allocation of  
125 mental resources to overcome obstacles in goal pursuit when carrying out a task” and is the  
126 basis for the Framework for Understanding Effortful Listening (FUEL) model.(27)  
127 Understanding speech in challenging hearing environments results in increased auditory and  
128 cognitive processing which can be observed objectively by measuring the pupil dilation  
129 during speech perception in noise, in a task such as the HINT(28-30)

## 131 **Rationale and Objectives**

132 This randomised controlled trial is designed to improve clinical decision-making for CI  
133 candidacy for patients with asymmetric hearing. It is necessary to establish more evidence to  
134 support the effectiveness and the fitting optimization of bimodal CI+HA versus HAs in patients  
135 with asymmetric hearing.

136 The first objective of the study is to evaluate the subjective (SSQ12) and objective (Hearing In  
137 Noise Test (HINT) which is word and sentence based and DANTALE I, which is monosyllabic  
138 word-based) benefits of a bimodal solution (CI+HA) compared to (HA+HA).

139 The second objective is to compare and evaluate patient self-reported outcomes with NCIQ,  
140 THI and DHI in the intervention group (CI+HA) with the control group (HA+HA).

141 The third objective is to evaluate if listening effort, hypothesized to cause fatigue, can be  
142 measured objectively by HINT with pupillometry.

143 To minimize listening effort and optimize the fitting of bimodal solution the CI fitting and  
144 loudness balancing on individual level will be evaluated.(2, 31, 32)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 147 **Methods and Analysis**

### 148 **Study Design, Ethics and Registration**

149 This study is a prospective randomised controlled trial based on a single centre conducted in  
150 Odense University Hospital, Denmark. The study started 01/02/2022 and is expected to end  
151 30/07/2024. It was successfully registered at ClinicalTrials.gov with registration number:  
152 NCT04919928.

153 This study has been approved at Research Ethics Committee Southern Denmark (Projekt-ID:  
154 S-20200074G) 21<sup>st</sup> August 2020 to 31<sup>st</sup> December 2024.

### 156 **Study Population**

157 Sixty participants with bilateral hearing-loss and asymmetric speech identification scores  
158 referred for CI surgery will be included (Figure 1).

### 160 **Inclusion Criteria**

- 161 • Adults >18 years old.
- 162 • Fluent in Danish, including reading and writing
- 163 • Acquired post-lingual deafness
- 164 • Use of bilateral HAs for at least one year prior to evaluation for cochlear implantation  
165 candidacy. This to ensure, that both ears have received auditive stimulation
- 166 • PTA > 40 dB HL in the ear considered for CI implantation and PTA $\geq$ 40 and  $\leq$  70dB HL in  
167 the contralateral ear in best aided condition, in quiet and in noise and in free field.

- 1  
2  
3  
4  
5 168 • SIS <70% in best aided condition in the ear considered for CI implantation and SIS ≥30%  
6  
7 169 and ≤70% in best aided condition in the contralateral ear, in quiet and in noise and in  
8  
9 170 free field.  
10  
11

## 12 171 Exclusion Criteria

- 13  
14  
15 172 • Vestibular loss in the ear not considered for CI implantation  
16  
17 173 • Surgical issues interfering with the site of implantation or anatomical contraindications  
18  
19 such as cochlear malformations, which will be determined using MRI or CT-scans.  
20 174  
21  
22 175 • Auditory nerve lesions.  
23  
24 176 • Central auditory pathway pathologies.  
25  
26  
27 177 • Otosclerosis.  
28  
29 178 • Single sided deafness (SSD).  
30  
31

## 32 179 Setup

33  
34  
35 180 A timeline of the study is shown in (Figure 2).  
36  
37

38 181 All enrolled participants will be tested with audiometry and v-HIT to determine hearing  
39  
40 182 thresholds and status of balance function during the first visit. Patients will receive new  
41  
42 183 replacement HAs. These HAs will be fitted during the second visit and if necessary refitted at  
43  
44 184 every visit in the clinic throughout the study. The baseline measurements will be conducted  
45  
46 185 when both groups have used the new replacement HAs to ensure acclimatisation. The  
47  
48 186 measurements are SIS in quiet and in noise with a signal-to-noise ratio (SNR) of 0dB using  
49  
50 187 DANTALE I speech material. The speech and masking white noise stimulus will be presented at  
51  
52 188 65 dB SPL in the free field. Stimuli will be presented as auditory stimuli only as well as with  
53  
54 189 visual cues, the latter to allow participants to use lipreading cues.  
55  
56  
57  
58  
59 190  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

191 Pupillometry variables are Peak Pupil Dilation (PPD), Mean Pupil Dilation (MPD), peak-time  
192 and standard deviation using HINT (sentences and words).

193 The HINT sentences are presented at a speech level of 65dB and initially an adaptive SNR is  
194 used to identify the SNR of 70% correct word recognition. The SNR at 70% correct word  
195 recognition is used as a fixed SNR during HINT test. The noise is multi-talker babble noise, in  
196 free field, tested in best aided condition. The pupillometry glasses is the Oticon Medical Pupil  
197 Labs glasses.

### 198 199 Recruitment, Stratification, Randomisation and Allocation

200 All eligible participants will sign a written, informed consent (supplementary file 1) in clinic  
201 after receiving verbal and written study information in Danish. The Danish consent form is  
202 available online at the Odense University Hospital Research Unit website.(33)

203 To ensure acclimatisation, participants will receive new replacement HAs fitted with the  
204 National Acoustic Laboratories (NAL) -non-linear (NL)<sup>2</sup> fitting algorithm one month before  
205 the experiment.

206 They will then undergo stratification, depending on the hearing thresholds. One group will  
207 consist of participants with PTA  $\geq$  70dB HL; and the other group will consist of subjects with  
208 PTA  $\leq$  70dB HL and  $\geq$  40 dB HL according to the inclusion criteria. The reason for this  
209 stratification is because pre-operative hearing thresholds may affect the measured outcomes  
210 in the study. Stratification ensures that both the intervention group and the control group will  
211 have an equal distribution of patients with profound hearing loss on the ear considered for  
212 implantation.

213

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

214 Then the participants will be randomly allocated into two groups: the intervention group  
215 (CI+HA) and the control group (HA+HA) according to 1:1 ratio using a blocked randomisation  
216 with randomly varying block size (4 or 6).

217 This randomisation will be accomplished using a computer-generated random sequence in  
218 Research Electronic Data Capture (REDCap), hosted by Odense Patient Explorative Network  
219 (OPEN) in the Region of Southern Denmark and developed by Vanderbilt University,  
220 Nashville, Tennessee, United States.(34)  
221 REDCap will also be used to send out the questionnaires to the participants' online mailbox  
222 (called Eboks in Denmark) throughout the study (see timeline (Figure 2)) and automatically  
223 save the data.

224 Participants will have the opportunity to return to their original HAs if they prefer to do so  
225 after one-month of acclimatisation.

### 227 Control Group

228 Thirty patients, who will be age-matched, randomised and allocated to the control group  
229 HA+HA will continue the use of the new replacement HAs for another three months (total four  
230 months of new replacement HA+HA use), serving as the delayed intervention control group.

### 232 Intervention Group

233 Thirty patients, who will be age-matched, randomised and allocated to the intervention group  
234 CI+HA will undergo surgery as soon as possible after the HA acclimatisation period.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 237 HA Fitting

238 The participant will receive either Phonak (Phonak Link M) or GN (ReSound LiNX Quattro or  
239 Resound ENZO Q) based on their personal preference. Both these HA models can be fitted  
240 with a CI by Advanced Bionics and Cochlear, respectively.

241 The HAs will be fitted according to NAL-NL2 procedures prescriptive fitting formula, which  
242 optimizes audibility in the bimodal solution(2) and will be verified with REM (Real Ear  
243 Measurement) to ensure that the HA is providing adequate gain and then further adjusted for  
244 comfort based on patient feedback.(35)

245 The new HAs will be prescribed to the patients free of charge and future service will also be  
246 free of charge.

247 Participants can drop out of the study if they do not want CI surgery. Collected data will be  
248 analysed if the patient still consents.

249

## 250 CI fitting

251 The CI will be selected depending on the participant's HA selection; that is, the CI that is  
252 compatible with the HA will be selected in order to ensure the most optimal bimodal fitting.

253 One-month post-surgery, the CI will be activated according to the settings and stimulation  
254 strategy based on patient's feedback. The CI will then be fitted with the HA according to the  
255 bimodal fitting formula allowing the HA to keep the NAL-NL2 fitting along with the wireless  
256 connection with the CI. (36, 37)

257 Patients hearing thresholds will be tested on CI activation day. The residual hearing will not  
258 be stimulated in this study.

259

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

260 All participants are offered standard rehabilitation with a speech therapist, including three  
261 visits a week up to 10 weeks following the initial fitting.

262 The training focuses on learning to identify different sounds from the environment and word  
263 discrimination.

264 The new CI will also be prescribed to the patients free of charge and future service will be free  
265 of charge as well.

266

### 267 Loudness Balancing

268 At 3- months follow-up the post-surgery complications will be evaluated and the levels in the  
269 CI will be adjusted if necessary.

270 In the loudness balancing procedure, the patient will have both the hearing aid and CI  
271 activated and at the 6-month follow-up, when the CI mapping levels are stable, patients will  
272 be randomised and assigned to one of three bimodal fitting groups:

273 Group A) will not complete any specific loudness balancing procedures, CI and HA will be  
274 fitted based on individual feedback from the patient.

275 Group B) will be fitted/finetuned using a bimodal loudness balancing task at a medium input  
276 level and adjusted based on the patient feedback. The audiologist will present a mid-level  
277 sound (approx. 55dB SPL (sound pressure level)) at the center-speaker.

278 Group C) will be fitted/finetuned using a bimodal loudness balancing task as group B but the  
279 audiologist will play three levels and adjust the gain for three input levels (soft, medium, and  
280 loud) according to the patient feedback.

281 For both groups B and C, the patient will be given a 'Bimodal Fusion' illustration (see Figure 3)  
282 and asked to provide feedback about the location of the sound by tracing over the line of the

1  
2  
3  
4 283 head. The HA gain will be adjusted using the bimodal adjustment option until the patient  
5  
6  
7 284 reports that the sounds are perceived at the center of the head.(24)

8  
9 285

10  
11  
12 286 **Primary Outcome**

13  
14 287 Primary outcomes are Speech intelligibility scores measured objectively with HINT  
15  
16 288 (sentences and words) and DANTALE I and subjectively with Speech, Spatial and Qualities of  
17  
18  
19 289 Hearing scale (SSQ-12). (9, 10, 22)

20  
21 290

22  
23  
24 291 **Secondary Outcome**

25  
26 292 Patient reported outcomes scores assessed with the Nijmegen Cochlear Implant  
27  
28  
29 293 Questionnaire (NCIQ), The Tinnitus Handicap Inventory (THI) and Dizziness Handicap  
30  
31 294 Inventory (DHI). (18, 20, 24)

32  
33 295

34  
35  
36 296 **Third Outcome**

37  
38 297 Listening effort assessed with pupil dilation with HINT.(10)

39  
40  
41 298

42  
43  
44 299 **Statistics**

45  
46 300 **Power calculation**

47  
48  
49 301 Power calculations with a power of 0.8 with a significance level of 0.05 have been made with  
50  
51  
52 302 STATA IC-15 using standard deviations for the HINT test and expected effect size (38) the  
53  
54 303 NCIQ(18), and the SSQ (internal communication with BEAR (Better Hearing Rehabilitation)  
55  
56 304 study on hearing aid use in Denmark) (Table 1). An estimated within participant standard  
57  
58  
59 305 deviation from the BEAR study of 1,9 in an HA population using the SSQ-12 is used to calculate  
60

the sample size. A difference of 1,4 will require 30 participants in each arm. The effect size is expected to be larger in the CI group which will lower the number of required subjects even further.

Based on this, 30 participants must be enrolled in each arm. Additional six patients (20%) in each arm will be enrolled in the study to account for dropouts.

Test	SD pre	SD post	Expected difference between the two treatment arms	Minimum required group size
1. HINT	6.3%	6.3%	5%	26
2. NCIQ - basic sound perception	14.4	23.5	53	4
2. NCIQ	13.4	19.6	34	6
2. NCIQ - speech perception	18.8	17.8	17	20
2.NCIQ Self-esteem	20.1	16.4	22	13
2.NCIQ Activity	23.0	15.9	27	10
2.NCIQ Social Interactions	19.8	14.5	25	9
3. SSQ Total	1.9	1.9	1.4	30

**Table 1:** Power calculations for the desired tests. Estimated within participant standard deviations (SD pre and SD post) with expected difference and the calculated required group size.

Detailed statistics is presented in the Statistical Analysis Plan (SAP) (supplementary file 2)

## Definition of Analysis Sets

Strategy for intention to treat analysis with incomplete observations.(39)

1. Attempt to follow-up on all randomised participants, even if they withdraw from allocated treatment.
2. Perform a main analysis of all observed data that are valid under a plausible assumption about the missing data.
3. Perform sensitivity analyses to explore the effect of deviations from the assumption made in the main analysis.
4. Account for all randomised participants, at least in the sensitivity analyses.



1  
2  
3  
4 325  
5

## 8 326 Analysis specification

10  
11 327 A constrained linear mixed model is used to analyse the outcome.

12  
13 328 The model will include randomisation group (CI+HA / HA+HA) and time (baseline/follow-up)  
14  
15 329 and their interaction as fixed effects along with the threshold strata that were used in stratifying  
16  
17  
18 330 the randomisation. The model is constrained so that the mean at baseline agrees across the two  
19  
20 331 treatment groups adjusted for threshold stratum, which is reasonable due to the randomisation  
21  
22  
23 332 of implant fitting. Patient ID will be included as a random effect to account for the repeated  
24  
25 333 measurements.

26  
27 334 Secondary outcomes will be analysed analogously in a constrained linear mixed model  
28  
29  
30 335 adjusting for randomisation strata. Model validation checks will be undertaken as described  
31  
32 336 above, switching to bootstrapping the standard errors when model assumptions are rejected.

33  
34  
35 337 Covariates such as age and gender will be included in all models.

36  
37  
38 338

## 41 339 Sensitivity analysis

42  
43  
44 340 Inclusion is performed conditional on Pure Tone Average (PTA) (from 0.5 to 4 kHz) PTA > 40  
45  
46 341 dB HL and SIS <50% in the ear considered for CI implantation and <70% in the best-aided  
47  
48  
49 342 condition which may lead to a truncation effect in the distribution of baseline measurements.  
50  
51 343 To address this, an analysis of covariance (ANCOVA) model conditioning on the baseline will be  
52  
53 344 used to obtain a sensitivity analysis estimate for the main outcome.(40)

54  
55  
56 345 The statistical analysis plan is attached as “supplementary file” along with the Data Description  
57  
58 346 listed in Appendix A (supplementary file 3).

59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

347

## **Patient and Public Involvement**

A focus-group interview was established with six cochlear implant patients. The patients commented on their decision to transition from HA to CI. Based on the feedback from the focus group, the research questions were developed.

The patients also reported problems with adjustments of the CI, when meeting the audiologist for CI adjustment controls.

354

## **Ethics and Dissemination**

Ethics approval for the conduct of this study was obtained from the Ethics Committee Southern Denmark, 21<sup>st</sup> August 2020 project ID S-20200074G.

The project is approved by the Danish Data Protection Agency (file no. 20/22868) in Region South Denmark.

All participants are treated according to current clinical standards regardless of the randomised study participation. The participants are volunteers and can at any moment withdraw their participation in the study without affecting their current or future treatment rights.

The Informed Consent form will be found online and it will be signed by all participants willing to participate the study and stored in their electronic journals in Department of Audiology, Odense University Hospital. All patients are given both oral and written information about the study.

368

369

1  
2  
3  
4 370  
5

## 6 7 371 **Results**

8  
9  
10 372 Results will be presented at national and international congresses and published in the  
11  
12 373 scientific literature for the attention of professional and scientific audiences on behalf of all  
13  
14 374 study sites and collaborators. A lay summary report will be published for patients and  
15  
16 375 members of the public.

18  
19 376

## 20 21 22 377 **Footnotes**

### 23 24 378 **Authors' Contributions:**

25  
26 379 YJ and JHS are involved in the conception of the study. LCA and JHS wrote the grant application and the draft of the  
27  
28 380 manuscript. JHS and YJ designed and revised the draft methodological content. YJ reviewed the manuscript and JHS critiqued  
29 381 it.

### 30 31 382 **Funding:**

32  
33 383 This study is funded by William Demant grant no. 19-3470 and Interfond grant no. 33.188

### 34 35 384 **Competing Interests:**

36 385 None declared.

### 37 38 386 **Contributorship Statement/Acknowledgements:**

39  
40 387 We are very thankful of the academiz English editing of Ph.D. Kathleen Faulkner Scalzo and Assistant Professor Lindsey Van  
41  
42 388 Yper.

43 389 We are grateful for the contribution from the patient advisers.

### 44 45 390 **Protocol and Registration:**

46  
47 391 This study is registered in ClinicalTrials.gov: NCT04919928

48  
49 392  
50 393

## 51 52 53 394 **Reference List**

54 395  
55 396 1. Morera C, Manrique M, Ramos A, Garcia-Ibanez L, Cavalle L, Huarte A, et al.  
56 397 Advantages of binaural hearing provided through bimodal stimulation via a cochlear implant  
57 398 and a conventional hearing aid: a 6-month comparative study. Acta Otolaryngol.  
58 399 2005;125(6):596-606.

60

- 1
- 2
- 3
- 4 400 2. Vroegop JL, Goedegebure A, van der Schroeff MP. How to Optimally Fit a Hearing
- 5 401 Aid for Bimodal Cochlear Implant Users: A Systematic Review. *Ear Hear.* 2018;39(6):1039-45.
- 6 402 3. Firszt JB, Holden LK, Reeder RM, Cowdrey L, King S. Cochlear implantation in
- 8 403 adults with asymmetric hearing loss. *Ear Hear.* 2012;33(4):521-33.
- 9 404 4. van Zon A, Peters JP, Stegeman I, Smit AL, Grolman W. Cochlear implantation for
- 10 405 patients with single-sided deafness or asymmetrical hearing loss: a systematic review of the
- 11 406 evidence. *Otol Neurotol.* 2015;36(2):209-19.
- 12
- 13 407 5. Thompson NJ, Dillon MT, Buss E, Rooth MA, King ER, Bucker AL, et al. Subjective
- 14 408 Benefits of Bimodal Listening in Cochlear Implant Recipients with Asymmetric Hearing Loss.
- 15 409 *Otolaryngol Head Neck Surg.* 2020;162(6):933-41.
- 16 410 6. Dillon MT, Buss E, Rooth MA, King ER, McCarthy SA, Bucker AL, et al. Cochlear
- 17 411 Implantation in Cases of Asymmetric Hearing Loss: Subjective Benefit, Word Recognition, and
- 18 412 Spatial Hearing. *Trends Hear.* 2020;24:2331216520945524.
- 19 413 7. van Loon MC, Smits C, Smit CF, Hensen EF, Merkus P. Cochlear Implantation in
- 20 414 Adults With Asymmetric Hearing Loss: Benefits of Bimodal Stimulation. *Otol Neurotol.*
- 22 415 2017;38(6):e100-e6.
- 23 416 8. The National Institute for Health and Care Excellence (NICE) 2019.
- 24 417 9. Elberling C, Ludvigsen C, Lyregaard PE. DANTALE: a new Danish speech material.
- 25 418 *Scand Audiol.* 1989;18(3):169-75.
- 26 419 10. Nielsen JB, Dau T. The Danish hearing in noise test. *Int J Audiol.* 2011;50(3):202-8.
- 27 420 11. Zhang E, Coelho DH. Beyond Sentence Recognition in Quiet for Older Adults:
- 29 421 Implications for Cochlear Implant Candidacy. *Otol Neurotol.* 2018;39(8):979-86.
- 30 422 12. Bronkhorst AW, Plomp R. The effect of head-induced interaural time and level
- 31 423 differences on speech intelligibility in noise. *J Acoust Soc Am.* 1988;83(4):1508-16.
- 32 424 13. Bronkhorst AW, Plomp R. Binaural speech intelligibility in noise for hearing-
- 33 425 impaired listeners. *J Acoust Soc Am.* 1989;86(4):1374-83.
- 34 426 14. Bronkhorst AW, Plomp R. A clinical test for the assessment of binaural speech
- 36 427 perception in noise. *Audiology.* 1990;29(5):275-85.
- 37 428 15. Choi SJ, Lee JB, Bahng J, Lee WK, Park CH, Kim HJ, et al. Effect of low frequency on
- 38 429 speech performance with bimodal hearing in bilateral severe hearing loss. *Laryngoscope.*
- 39 430 2016;126(12):2817-22.
- 40 431 16. Balkenhol T, Wallhäusser-Franke E, Rotter N, Servais JJ. Cochlear Implant and
- 42 432 Hearing Aid: Objective Measures of Binaural Benefit. *Front Neurosci.* 2020;14:586119.
- 43 433 17. Devlin NJ AJ. Getting the most of proms: putting health outcomes at the heart of
- 44 434 NHS decision-making. London, Kings Fund and Office of Health Economics 2010.
- 45 435 18. Hinderink JB, Krabbe PF, Van Den Broek P. Development and application of a
- 46 436 health-related quality-of-life instrument for adults with cochlear implants: the Nijmegen
- 47 437 cochlear implant questionnaire. *Otolaryngol Head Neck Surg.* 2000;123(6):756-65.
- 48 438 19. Hughes SE, Hutchings HA, Rapport FL, McMahon CM, Boisvert I. Social
- 50 439 Connectedness and Perceived Listening Effort in Adult Cochlear Implant Users: A Grounded
- 51 440 Theory to Establish Content Validity for a New Patient-Reported Outcome Measure. *Ear Hear.*
- 52 441 2018;39(5):922-34.
- 53 442 20. Jacobson GP, Newman CW. The development of the Dizziness Handicap Inventory.
- 54 443 *Arch Otolaryngol Head Neck Surg.* 1990;116(4):424-7.
- 55 444 21. Mertens G, De Bodt M, Van de Heyning P. Cochlear implantation as a long-term
- 57 445 treatment for ipsilateral incapacitating tinnitus in subjects with unilateral hearing loss up to 10
- 58 446 years. *Hear Res.* 2016;331:1-6.
- 59
- 60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

22. Noble W, Jensen NS, Naylor G, Bhullar N, Akeroyd MA. A short form of the Speech, Spatial and Qualities of Hearing scale suitable for clinical use: the SSQ12. *Int J Audiol*. 2013;52(6):409-12.
23. Servais JJ, Hörmann K, Wallhäusser-Franke E. Unilateral Cochlear Implantation Reduces Tinnitus Loudness in Bimodal Hearing: A Prospective Study. *Front Neurol*. 2017;8:60.
24. Zachariae R, Mirz F, Johansen LV, Andersen SE, Bjerring P, Pedersen CB. Reliability and validity of a Danish adaptation of the Tinnitus Handicap Inventory. *Scand Audiol*. 2000;29(1):37-43.
25. Winn MB, Edwards JR, Litovsky RY. The Impact of Auditory Spectral Resolution on Listening Effort Revealed by Pupil Dilation. *Ear Hear*. 2015;36(4):e153-65.
26. Zekveld AA, Kramer SE, Festen JM. Pupil response as an indication of effortful listening: the influence of sentence intelligibility. *Ear Hear*. 2010;31(4):480-90.
27. Pichora-Fuller MK, Kramer SE, Eckert MA, Edwards B, Hornsby BW, Humes LE, et al. Hearing Impairment and Cognitive Energy: The Framework for Understanding Effortful Listening (FUEL). *Ear Hear*. 2016;37 Suppl 1:5s-27s.
28. Ohlenforst B, Zekveld AA, Lunner T, Wendt D, Naylor G, Wang Y, et al. Impact of stimulus-related factors and hearing impairment on listening effort as indicated by pupil dilation. *Hear Res*. 2017;351:68-79.
29. Wendt D, Koelewijn T, Książek P, Kramer SE, Lunner T. Toward a more comprehensive understanding of the impact of masker type and signal-to-noise ratio on the pupillary response while performing a speech-in-noise test. *Hear Res*. 2018;369:67-78.
30. Eckert MA, Teubner-Rhodes S, Vaden KI, Jr. Is Listening in Noise Worth It? The Neurobiology of Speech Recognition in Challenging Listening Conditions. *Ear Hear*. 2016;37 Suppl 1(Suppl 1):101s-10s.
31. Francart T, McDermott HJ. Psychophysics, fitting, and signal processing for combined hearing aid and cochlear implant stimulation. *Ear Hear*. 2013;34(6):685-700.
32. Wang Y, Naylor G, Kramer SE, Zekveld AA, Wendt D, Ohlenforst B, et al. Relations Between Self-Reported Daily-Life Fatigue, Hearing Status, and Pupil Dilation During a Speech Perception in Noise Task. *Ear Hear*. 2018;39(3):573-82.
33. Jakobsen Y, Schmidt JH. Behandling af nedsat hørelse med cochlear implantat (CI) og høreapparat i kombination i forhold til høreapparater alene. 2022. <https://ouh.dk/media/vwihy4wi/deltagerinformation-for-bimodal-med-lodtr%C3%A6kning.pdf> (accessed 21. Aug. 2022).
34. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42(2):377-81.
35. Digeser FM, Engler M, Hoppe U. Comparison of bimodal benefit for the use of DSL v5.0 and NAL-NL2 in cochlear implant listeners. *Int J Audiol*. 2020;59(5):383-91.
36. Cuda D, Murri A, Mainardi A, Chalupper J. Effectiveness and efficiency of a dedicated bimodal fitting formula. *Audiol Res*. 2019;9(1):219.
37. Stronks HC, Briaire JJ, Frijns JHM. The Temporal Fine Structure of Background Noise Determines the Benefit of Bimodal Hearing for Recognizing Speech. *J Assoc Res Otolaryngol*. 2020;21(6):527-44.
38. Poissant SF, Bero EM, Busekroos L, Shao W. Determining cochlear implant users' true noise tolerance: use of speech reception threshold in noise testing. *Otol Neurotol*. 2014;35(3):414-20.

- 1  
2  
3  
4 493 39. White IR, Horton NJ, Carpenter J, Pocock SJ. Strategy for intention to treat analysis  
5 494 in randomised trials with missing outcome data. *Bmj*. 2011;342:d40.  
6 495 40. Liu GF, Lu K, Mogg R, Mallick M, Mehrotra DV. Should baseline be a covariate or  
8 496 dependent variable in analyses of change from baseline in clinical trials? *Stat Med*.  
9 497 2009;28(20):2509-30.  
10 498  
11 499  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure 1**





Figure 2



<sup>1</sup>Estimating hearing status pre-surgery

<sup>2</sup>Video Head Impulse Test v-HIT: clinical -routine measure.

<sup>3</sup>Hearing in noise test. Quiet and noise. Fixed SNR = +10dB. Free field with HAs


<sup>4</sup>Speech Identification Score: Words and sentences. Auditory and audiovisual. In quiet and in noise.

<sup>5</sup>Peak Pupil Dilation (PPD)

<sup>6</sup>Questionnaires: Speech, Spatial and Qualities-12 (SSQ-12), Nijmegen Cochlear Implant Questionnaire (NCIQ), Tinnitus Handicap Inventory (THI), Dizziness Handicap Inventory (DHI) will all be distributed by using REDCap to participants digital mail-box.

<sup>7</sup>The three groups are described in detail in the protocol.



**Figure 3**

This diagram that will be placed in front of the patient to track that the sound is balanced by indicating where they hear it. A sound will be presented in front of the listener and hearing aid gain is adjusted until the patient hears the sounds 'fused' or that it is coming from the same location/sounds centered. The figure will be used for group B and C. (The diagram is created by YJ)

# Deltagerinformation

-om deltagelse i et videnskabeligt forsøg

## Behandling af nedsat hørelse med cochlear implantat (CI) og høreapparat i kombination i forhold til høreapparater alene.

### Projektets originale titel:

Fordele ved bimodal tilpasning med cochlear implantat og høreapparat sammenlignet med dobbeltsidig høreapparat hos patienter med asymmetrisk taleforståelse: Et kontrolleret lodtrækningsforsøg

Øre-Næse-Halskirurgisk/Høreklubben

Odense Universitetshospital

## Kære deltager

Kære Deltager

Vi vil spørge, om du vil deltage i et videnskabeligt forsøg.

Før du beslutter, om du vil deltage i forsøget, skal du fuldt ud forstå, hvad forsøget går ud på, og hvorfor vi gennemfører forsøget.

Vi vil derfor bede dig om at læse denne deltagerinformation grundigt.

Der er to QR koder i denne deltagerinformation, som beskriver projektet mere kortfattet.

Inden du kan indgå i forsøget, vil du ligeledes modtage mundtlig information af den forsøgsansvarlige læge.

Hvis du beslutter dig for at deltage i forsøget, vil vi bede dig om at underskrive en samtykkeerklæring. Denne samtykkeerklæring giver de forsøgsansvarlige mulighed for at få direkte adgang til relevante oplysninger i din journal for at kunne indsamle data, gennemføre, overvåge og kontrollere forsøget.

De oplysninger, der indsamles fra din journal vil være helbredsoplysninger, tidligere og aktuelle skanninger af forhold omkring øret, oplysninger om evt. øreoperationer og behandling med høreapparater samt resultater af de undersøgelser, vi udfører, og som du tidligere har fået udført omkring hørelse og balancefunktion.

Det vil kun være den forsøgsansvarlige læge og projektkoordinator, der har adgang til din journal i forbindelse med gennemførelse af forsøget. De relevante oplysninger fra din journal registreres i anonymiseret form i en database sammen med de data, der indsamles som en del af forsøget.

Samarbejdspartnere (producenter af måleapparater) har ikke adgang til din journal, men kan dog få adgang til en afgrænset del af data i anonymiseret form, når der opstår et specifikt behov herfor. Det kan f.eks. være relevant, hvis de forsøgsansvarlige får behov for teknisk hjælp i forbindelse med behandling af data. En sådan dataadgang vil kun blive givet, hvis der foreligger en godkendt databehandlaftale mellem virksomheden og Region Syddanmark, der er den dataansvarlige myndighed.

Husk, at du har ret til betænkningstid, før du beslutter, om du vil underskrive samtykkeerklæringen. Det er frivilligt at deltage i forsøget. Du kan når som helst trække dit samtykke tilbage. Det har stor gavn for forskningen at kende årsagen til, at du ikke ønsker at deltage, men du skal naturligvis ikke oplyse årsagen, hvis ikke du ønsker det.

Det vil ikke få konsekvenser for din behandling.

Hvis der er behov for ekstra besøg på Høreklinikken på Odense Universitetshospital i forbindelse med forsøget, vil der blive betalt transportgodtgørelse herfor.

Forsøget er et samarbejde mellem, Øre-næse-hals kirurgisk afdeling og Høreklinikken på Odense Universitetshospital, og Øre-Næse-halskirurgisk og Audiologisk afdeling på Rigshospitalet.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15 På de følgende sider kan du læse, hvad det vil  
16 betyde for dig, hvis du vælger at deltage i  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

På de følgende sider kan du læse, hvad det vil  
betyde for dig, hvis du vælger at deltage i  
forsøget.

Afslutningsvist kommer de sider, hvor både du  
og lægen, der informerer dig, skal skrive  
under.

## FORMÅL MED FORSØGET

Du er blevet spurgt, om du vil deltage i dette forsøg, fordi du har nedsat hørelse i svær grad og er derfor tilbudt operation med et høreimplantat = cochlear implantat også kaldet et CI, på det dårligst hørende øre.



Formålet med dette forsøg er at undersøge, hvilken behandling, der giver den bedste hørelse for dig som patient.

Alle patienter, der indgår i forsøget, får tilpasset to nye høreapparater, der kan tilpasses med et CI. Høreapparaterne skal man anvende og vænne sig til at bruge i ca. 1 måned.

Herefter trækkes der lod om du udvælges til at få en CI operation på det dårligst hørende øre og fortsætte med at anvende det nye høreapparat på det andet øre eller om du udvælges til at være i den anden gruppe som fortsætter yderligere 3 måneder med begge høreapparater for derefter at tilbydes CI operation.

Formålet er at undersøge om patienter hører bedre med et CI der kan arbejde sammen med et høreapparat sammenlignet med bedst tilpasset høreapparat behandling.



Vi vil undersøge mange aspekter af hørelsen herunder lydopfattelse med høreprøver og tests af taleforståelighed. Desuden vil vi som noget nyt måle på bevægelsen af dine øjne (pupiller), når du gennemfører disse tests. Dette har til formål at undersøge, hvor meget du anstrenger dig for at høre i de forskellige test situationer.

Hvis du bliver så glad for dine nye høreapparater at du ikke længere ønsker en operation med et CI, så får du selvfølgelig lov til at aflyse operationen.

Dette forsøg er vigtigt i forhold at forbedre retningslinjer med henblik på at give en mere præcis vurdering for den enkelte patient i forhold til at operere en patient med nedsat hørelse eller fortsætte behandling med høreapparater.

Alle høreapparater og høreimplantater, der anvendes til forsøget, er godkendte, og de er alle tilgængelige behandlingsmuligheder på klinikker i Danmark, hvor man udfører behandling med høre-implantater

Forsøget har brug for 60 deltagere i alt.

## NYTTE VED FORSØGET

CI er i rivende udvikling, men desværre er en behandling med disse ikke helt uden konsekvenser for dig som patient. En operation med et høreimplantat giver en risiko for at udvikle permanent svimmelhed, forstyrrelser af smagssansen, og påvirkning af ansigtsnerven samt infektion.

Det er ikke altid, at hørelsen forbedres så meget som ønsket ved en behandling med CI. Nogle patienter kan opleve øresusen (tinnitus) efter operationen, mens andre oplever at et CI har behandlet deres tinnitus.

I nogle situationer kan der være fordele ved høreapparatbehandling, frem for behandling med CI eks. hvis man lytter til musik eller når man taler i telefon. Derimod kan et CI give en bedre forståelse af tale i mindre forsamlinger end det opleves med et høreapparat.

Det forventes at alle disse fordele kan opleves med den bimodale løsning (et CI kombineret med et høreapparat).

Stærkt nedsat hørelse forringer livskvaliteten hos de fleste, det er derfor vigtigt, at du som patient kan tilbydes og hjælpes med den behandling, der er den helt rigtige for dig.

En behandling med et CI kan ikke laves om, så derfor er det meget vigtigt, at behandlingen tilbydes på det helt rigtige tidspunkt.

Fordelene ved behandlingen med et CI skal overstige de mulige ulemper for dig som patient.

Dette forsøg vil bidrage til, at sundhedspersonale, der arbejder med hørehæmmede, bliver bedre til at rådgive dig som patient, om det helt rigtige tidspunkt for at få foretaget en operation med et CI. Desuden indeholder forsøget en række andre og nye tests, der vil kunne anvendes til fremtidige patienter, hvis netop disse tests viser sig at kunne hjælpe dig som patient i samarbejde med sundhedspersonalet til at træffe den bedste beslutning for behandlingen af høretab.

Som patient vil man være meget sikker på, at man får et optimalt udbytte af behandlingen, og dette er også afgørende for det sundhedspersonale, der skal rådgive dig. Derfor vil et forsigtighedsprincip ofte gøre, at man i nogle situationer ikke ønsker eller ikke får tilbudt den behandling, der i virkeligheden var den, der kunne forbedre hørelsen og dermed livskvaliteten mest muligt.

Resultaterne af dette forsøg vil rykke ved de behandlingsgrænser, som vi i dag anvender, når vi skal behandle patienter med et svært høretab.

Dette projekt kan bane vej for, at hørehæmmede får bedre hørelse og taleforståelse samt højere livskvalitet.

## **BIVIRKNINGER, RISICI, KOMPLIKATIONER OG ULEMPER**

Du vil som deltager i dette studie få den sædvanlige information om bivirkninger og kendte komplikationer i relation til behandlingen med CI. Denne information findes i den patientfolder, som du har fået udleveret på Høreklinikken

I forbindelse med dette forsøg vil der ikke være bivirkninger, risici eller komplikationer udover dem, som du kan risikere i forbindelse med en behandling med et høreimplantat.

Ulemperne vil være, at halvdelen af deltagerne i dette studie skal vente yderligere 3 mdr. på operationen med CI, da effekten af de nye høreapparater skal afprøves og testes i denne gruppe.

## **PLAN FOR FORSØGET**

Forsøget vil vare lidt over et år fra den dato, hvor du tilbydes behandling med høreimplantat. Du bliver undersøgt min. 4 gange efter operationen, hvilket er fastlagt 1,3,6 og 12 måneder efter operationen. Derudover er der opfølgninger som er standard procedure, når man får et CI.

Undersøgelserne udføres af en læge sammen med en audiolog eller audiologiassistent.

Undersøgelserne omfatter følgende:

Spørgeskemaer, der vil blive sendt til dig forud for undersøgelsestidspunktet.

Forskellige høreprøver af tone-opfattelse og tale forståelighed med og uden høreapparater.

Undersøgelse af din balancefunktion.

Observation af øjne (pupiller) i forbindelse med gennemførelse af test for tale forståelighed.

## **OPLYSNINGER OM ØKONOMISKE FORHOLD**

Forsøget er støttet med en bevilling på 2.798.250 kr. fra William Demant Fonden, der indsættes på forskningskonto på Odense Universitetshospital. Bevillingen er givet som et totalt beløb for hele projektet, og det er ikke afhængt af, hvor mange patienter, der deltager i projektet. Herudover er der en bevilling på 180.000 kr. fra Interfond, der ligeledes indsættes på forskningskonto på Odense Universitetshospital. Forsøget er således støttet med 2.978.250 kr. I alt 2.165.000 kr. er afsat til aflønning af forskere og hjælpepersonale, der er ansat på Odense Universitetshospital i hele projektperioden, og som kan frikøbes helt eller delvist til gennemførelse af projektet. Der er ikke personer tilknyttet forskningsprojektet, som får særskilt honorering ud over den løn, der oppebæres ved ansættelse på Odense Universitetshospital, i forbindelse med gennemførelse af projektet.

Et evt. tilbageværende overskydende støttebeløb efter projektperioden vil blive forsøgt anvendt inden for projektets formål eks. til udgivelse af videre forskningsresultater på baggrund af undersøgelsen eller returneret som ubrugte midler til William Demant Fonden og Interfond.

## KOMPENSATION TIL FORSØGSPERSONER

Du kan som forsøgsperson ikke få betaling for deltagelse i forsøget, da forsøget udføres som en del af de normale besøg på høreklubben, dog gives der transportgodtgørelse efter gældende regler og derudover, hvis der er såfremt der måtte opstå ekstra besøg mhp. flere undersøgelser.

## ADGANG TIL FORSØGSRESULTATER

Du kan som forsøgsperson få oplysninger om forsøgets resultater ved at henvende dig til den forsøgsansvarlige. Resultater vil dog ikke være tilgængelige før tidligst 2 år efter, at du er inkluderet i forsøget. Du vil kunne få resultater af dine egne tests umiddelbart efter de er foretaget, men de samlede forsøgs hovedresultater vil først være tilgængelige, når alle deltagerne i forsøget har gennemført alle tests.

## AFSLUTNING

Vi håber, at du med denne information har fået tilstrækkeligt indblik i, hvad det vil sige at deltage i forsøget, og at du føler dig rustet til at tage beslutningen om din eventuelle deltagelse.

Vi beder dig også om at læse det vedlagte materiale "Forsøgspersoners rettigheder i et sundhedsvidenskabeligt forskningsprojekt".



**KONTAKTPERSONER**

Hvis du vil vide mere, er du meget velkommen til at os.

**PROJEKTKOORDINATOR:**

Læge Yeliz Jakobsen

[Yeliz.jakobsen@rsyd.dk](mailto:Yeliz.jakobsen@rsyd.dk)

Tlf: 65412536

**FORSØGSANSVARLIG LÆGE:**

Jesper Hvass Schmidt overlæge, ph.d.

Øre-næse-hals/Høreklubben afd. F

Odense Universitetshospital

Klinisk lektor, Klinisk Institut

Syddansk Universitet

[Jesper.schmidt@rsyd.dk](mailto:Jesper.schmidt@rsyd.dk)

Tlf: 65412536

**BILAG:**

- ”Forsøgspersonens rettigheder i et sundhedsvidenskabeligt forskningsprojekt”
- Komitesystemets fortrykte samtykkeerklæringer.

## Forsøgspersoners rettigheder i et sundhedsvidenskabeligt forskningsprojekt

Som deltager i et sundhedsvidenskabeligt forskningsprojekt skal du vide, at:

- Din deltagelse i forskningsprojektet er helt frivillig og kun kan ske efter, at du har fået både skriftlig og mundtlig information om forskningsprojektet og underskrevet samtykkeerklæringen.
- Du til enhver tid mundtligt, skriftligt eller ved anden klar tilkendegivelse kan trække dit samtykke til deltagelse tilbage og udtræde af forskningsprojektet. Såfremt du trækker dit samtykke tilbage påvirker dette ikke din ret til nuværende eller fremtidig behandling eller andre rettigheder, som du måtte have.
- Du har ret til at tage et familiemedlem, en ven eller en bekendt med til informations samtalen.
- Du har ret til betænkningstid, før du underskriver samtykkeerklæringen.
- Oplysninger om dine helbredsforhold, øvrige rent private forhold og andre fortrolige oplysninger om dig, som fremkommer i forbindelse med forskningsprojektet, er omfattet af tavshedspligt.
- Behandling af oplysninger om dig, herunder oplysninger i dine blodprøver og væv, sker efter reglerne i databeskyttelsesforordningen, databeskyttelsesloven samt sundhedsloven. Den dataansvarlige i forsøget skal orientere dig nærmere om dine rettigheder efter databeskyttelsesreglerne.
- Der er mulighed for at få aktindsigt i forsøgsprotokoller efter offentlighedslovens bestemmelser. Det vil sige, at du kan få adgang til at se alle papirer vedrørende forsøgets tilrettelæggelse, bortset fra de dele, som indeholder forretningshemmeligheder eller fortrolige oplysninger om andre.
- Der er mulighed for at klage og få erstatning efter reglerne i lov om klage- og erstatningsadgang inden for sundhedsvæsenet. Hvis der under forsøget skulle opstå en skade kan du henvende dig til Patienterstatningen, se nærmere på [www.patienterstatningen.dk](http://www.patienterstatningen.dk)

### De Videnskabsetiske Komiteer for Region Hovedstaden (6 komiteer)

Tlf.: +45 38 66 63 95  
E-mail: [vek@regionh.dk](mailto:vek@regionh.dk)  
Hjemmeside:  
[www.regionh.dk/vek](http://www.regionh.dk/vek)

### Den Videnskabsetiske Komité for Region Sjælland

Tlf.: +45 93 56 60 00  
E-mail: [RVK-sjaelland@regionsjaelland.dk](mailto:RVK-sjaelland@regionsjaelland.dk)  
Hjemmeside:  
<https://www.regionsjaelland.dk/sundhed/forskning/forfagfolk/videnskabsetisk-komite/Sider/default.aspx>

### De Videnskabsetiske Komiteer for Region Syddanmark (2 komiteer)

Tlf.: + 45 76 63 82 21  
E-mail: [komite@rsyd.dk](mailto:komite@rsyd.dk)  
Hjemmeside:  
[www.regionsyddanmark.dk/komite](http://www.regionsyddanmark.dk/komite)

### De Videnskabsetiske Komiteer for Region Midtjylland (2 komiteer)

Tlf.: +45 78 41 01 83  
/ +45 78 41 01 82 / +45 78  
41 01 81  
E-mail: [komite@rm.dk](mailto:komite@rm.dk)  
Hjemmeside:  
[www.komite.rm.dk](http://www.komite.rm.dk)

### Den Videnskabsetiske Komité for

Region Nordjylland Tlf.: +45  
97 64 84 40  
E-mail: [vek@rn.dk](mailto:vek@rn.dk)  
Hjemmeside: [www.rn.dk/vek](http://www.rn.dk/vek)

### National Videnskabsetisk Komité

Tlf.: +45 72 21 68 55  
E-mail: [kontakt@nvk.dk](mailto:kontakt@nvk.dk)  
Hjemmeside: [www.nvk.dk](http://www.nvk.dk)

1  
2  
3 **(S1) Informeret samtykke til deltagelse i et sundhedsvidenskabeligt forskningsprojekt.**  
4

5 **Forskningsprojektets titel:**

6  
7 Behandling af nedsat hørelse med cochlear implantat og høreapparat i kombination i forhold  
8 til høreapparater alene.  
9

10 **Projektets originale titel:** Fordele ved bimodal tilpasning med cochlear implantat og  
11 høreapparat sammenlignet med dobbeltsidig høreapparat hos patienter med asymmetrisk  
12 taleforståelse: Et kontrolleret lodtrækningsforsøg.  
13

14 **Erklæring fra forsøgspersonen:**

15  
16 Jeg har fået skriftlig og mundtlig information og jeg ved nok om formål, metode, fordele og  
17 ulemper til at sige ja til at deltage.  
18

19 Jeg ved, at det er frivilligt at deltage, og at jeg altid kan trække mit samtykke tilbage uden at  
20 miste mine nuværende eller fremtidige rettigheder til behandling.  
21

22 Jeg giver samtykke til, at deltage i forskningsprojektet, og har fået en kopi af dette  
23 samtykkeark samt en kopi af den skriftlige information om projektet til eget brug.  
24  
25

26 Forsøgspersonens navn: \_\_\_\_\_  
27

28  
29 Dato: \_\_\_\_\_ Underskrift: \_\_\_\_\_  
30  
31

32  
33 Ønsker du at blive informeret om forskningsprojektets resultat samt eventuelle konsekvenser  
34 for dig?:  
35

36 Ja \_\_\_\_\_ (sæt x)      Nej \_\_\_\_\_ (sæt x)  
37

38 Ønsker du at blive kontaktet ved fremtidige projekter på Høreklinikken/Øre-næse-hals afd.?:  
39

40 Ja \_\_\_\_\_ (sæt x)      Nej \_\_\_\_\_ (sæt x)  
41  
42

43 **Erklæring fra den, der afgiver information:**

44  
45 Jeg erklærer, at forsøgspersonen har modtaget mundtlig og skriftlig information om forsøget.  
46

47 Efter min overbevisning er der givet tilstrækkelig information til, at der kan træffes  
48 beslutning om deltagelse i forsøget.  
49

50 Navnet på den, der har afgivet information: \_\_\_\_\_  
51  
52

53  
54 Dato: \_\_\_\_\_ Underskrift: \_\_\_\_\_  
55  
56

57 Projektidentifikation: Sagsnummer 20202000-84  
58  
59  
60

## Statistical analysis plan (SAP) for randomised clinical studies.

<b>Project responsible</b> Consultant Jesper Hvass Schmidt and Ph.D. student Yeliz Jakobsen
<b>Title</b> A Study Protocol for a Randomised Controlled Trial Evaluating the Benefits from Bimodal Solution with Cochlear Implant and Hearing Aids vs. Bilateral Hearing Aids in Patients with Asymmetric Speech Identification Scores.
<b>Deadline</b> 30.07.2024
<b>Study design</b> Randomised controlled trial
<b>Sample size</b> 60 participants
<b>Aim</b> This randomised controlled trial is designed to improve clinical decision-making for CI candidacy for patients with asymmetric hearing. It is necessary to establish more evidence to support the effectiveness and the fitting optimization of bimodal CI+HA versus HAs in patients with asymmetric hearing.

1  
2  
3  
4  
5  
6 The first objective of the study is to evaluate the subjective (SSQ12) and objective (Hearing  
7 In Noise Test (HINT) which is word and sentence based and DANTALE I, which is  
8 monosyllabic word-based) benefits of a bimodal solution (CI+HA) compared to (HA+HA).  
9  
10  
11  
12 The second objective is to compare and evaluate patient self-reported outcomes with NCIQ,  
13 THI and DHI in the intervention group (CI+HA) with the control group (HA+HA).  
14  
15  
16 The third objective is to evaluate if listening effort, hypothesized to cause fatigue, can be  
17 measured objectively by HINT with pupillometry.  
18  
19  
20 To minimize listening effort and optimize the fitting of bimodal solution the CI fitting and  
21 loudness balancing on individual level will be evaluated.  
22  
23  
24  
25  
26  
27  
28

### 29 **Hypothesis**

30  
31 Patients treated with a CI on the poorer hearing ear and a HA to the better hearing ear  
32 (CI+HA) in a bimodal solution have increased objective and subjective measured speech  
33 intelligibility compared to patients treated with new bilateral replacement hearing aids  
34 (HA+HA).  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

## 49 **2) Data description**

50 See Appendix A  
51

## 52 **3) The statistical analysis plan (SAP)**

### 53 **Definition of outcome**

54  
55  
56  
57 Primary Outcome  
58  
59  
60

Primary outcomes are Speech intelligibility scores measured objectively with HINT (sentences and words) and DANTALE I and subjectively with Speech, Spatial and Qualities of Hearing scale (SSQ-12).

#### Secondary Outcome

Patient reported outcomes scores assessed with the Nijmegen Cochlear Implant Questionnaire (NCIQ), The Tinnitus Handicap Inventory (THI) and Dizziness Handicap Inventory (DHI).

#### Third Outcome

Listening effort assessed with pupil dilation with HINT.

#### **Definition of treatment variables**

Treatments are HAs and CI-surgery assigned by randomisation. The primary comparison will be between the CI+HA and HA+HA groups.

#### **Covariates used in analyses**

Stratified randomisation for thresholds of the ear to be implanted.

#### **Definition of effect size/parameter of interest**

Primary effect size:

Objective outcome: Mean difference in HINT in quiet and in noise between intervention group (HA+CI) and control group (HA+HA) at 3, 6 and 12 months follow-up post- bimodal CI+HA-fitting and 3 months post-HA-fitting respectively.

1  
2  
3  
4  
5  
6 Subjective outcome: Mean difference in SSQ-12-scores at 3, 6 and 12 months follow-up  
7  
8 post- bimodal CI+HA-fitting and 3 months post-HA-fitting respectively  
9

### 10 **Definition of Analysis Sets**

11  
12 Strategy for intention to treat analysis with incomplete observations.<sup>1)</sup>

- 13 1. Attempt to follow-up on all randomised participants, even if they withdraw from  
14 allocated treatment.
- 15 2. Perform a main analysis of all observed data that are valid under a plausible  
16 assumption about the missing data.
- 17 3. Perform sensitivity analyses to explore the effect of deviations from the assumption  
18 made in the main analysis.
- 19 4. Account for all randomised participants, at least in the sensitivity analyses.

20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33 1)

34  
35  
36 White, Ian R., Nicholas J. Horton, James Carpenter, and Stuart J. Pocock. 2011. 'Strategy for  
37 Intention to Treat Analysis in Randomised Trials with Missing Outcome Data'. *BMJ* 342  
38  
39 (February): d40. <https://doi.org/10.1136/bmj.d40>.  
40  
41  
42  
43  
44  
45

### 46 **Analysis specification**

47  
48 A constrained linear mixed model is used to analyse the outcome.

49  
50 The model will include randomisation group (CI+HA / HA+HA) and time (baseline/follow-  
51 up) and their interaction as fixed effects along with the threshold strata that were used in  
52 stratifying the randomisation. The model is constrained so that the mean at baseline agrees  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 across the two treatment groups adjusted for threshold stratum, which is reasonable due to  
7  
8 the randomisation of implant fitting. Patient ID will be included as a random effect to account  
9  
10 for the repeated measurements.

11  
12 Secondary outcomes will be analysed analogously in a constrained linear mixed model  
13  
14 adjusting for randomisation strata. Model validation checks will be undertaken as described  
15  
16 above, switching to bootstrapping the standard errors when model assumptions are rejected.  
17  
18

19  
20 Covariates such as age and gender will be included in all models.  
21  
22  
23  
24  
25

### 26 **Sensitivity analysis**

27  
28 Inclusion is performed conditional on Pure Tone Average (PTA) (from 0.5 to 4 kHz) PTA >  
29  
30 40 dB HL and SIS <50% in the ear considered for CI implantation and <70% in the best-aided  
31  
32 condition which may lead to a truncation effect in the distribution of baseline measurements.  
33  
34 To address this, an analysis of covariance (ANCOVA) model conditioning on the baseline will  
35  
36 be used to obtain a sensitivity analysis estimate for the main outcome. (2)  
37  
38

39  
40 The statistical analysis plan is attached as “supplementary file” along with the Data  
41  
42 Description listed in Appendix A.  
43  
44

45  
46 2)

47  
48 Liu, Guanghan F., Kaifeng Lu, Robin Mogg, Madhuj Mallick, and Devan V. Mehrotra. ‘Should  
49  
50 Baseline Be a Covariate or Dependent Variable in Analyses of Change from Baseline in  
51  
52 Clinical Trials?: ANALYSES OF CHANGE FROM BASELINE IN CLINICAL TRIALS’. *Statistics in*  
53  
54 *Medicine* 28, no. 20 (10 September 2009): 2509–30. <https://doi.org/10.1002/sim.3639>.  
55  
56  
57  
58  
59  
60





1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

# DATA DESCRIPTION

## APPENDIX A

Variable name	Content	Datatype	Missing	Excepted range (numeric data)
Inc_date	Date of inclusion	ddmmyy	No missing	

### Confounders

Age	Age at baseline	numeric	No missing	18-110
Sex		binary	No missing	
Medicine	Pupil-constricting/dilating	numeric	No missing	

### Before CI surgery

Variable name	Content	Datatype	Missing	Excepted range (numeric data)
<b>TRESHOLDS</b> Day 0 Baseline	The patient can be tested at frequencies from 125 Hz up to 8 kHz. Tresholds is tested with headphones and , each ear is tested separately, unaided. The masker is only added when there is a air bone gap >10dB at puretone audiometry	Numeric	Missing possible	0 to 120 db HL
<b>HINT</b> (word) Day 0 Baseline (One month with new replacement HA) Quiet HA right ear	Number of correct words or sentences out of 20 sentences with 5 words pr sentence. In free field. Speech level at 65dB HL.	Numeric	Missing possible	0-100%
<b>HINT</b> (word) Day 0 Baseline (One month with new replacement HA) Quiet HA left ear	Number of correct words or sentences out of 20 sentences with 5 words pr sentence In free field. Speech level at 65dB HL.	Numeric	Missing possible	0-100%

1 2 3 4 5 6 7 8 9 10	<b>HINT (word)</b> Day 0 Baseline (One month with new replacement HA) Quiet HA+HA	Number of correct words or sentences out of 20 sentences with 5 words pr sentence In free field. Speech level at 65dB HL.	Numeric	Missing possible	0-100%
11 12 13 14 15 16 17	<b>HINT (sentence)</b> Day 0 Baseline (One month with new replacement HA) Quiet HA right ear	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Missing possible	0-100%
18 19 20 21 22	<b>HINT (sentence)</b> Day 0 Baseline (One month with new replacement HA) Quiet HA left ear	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Missing possible	0-100%
23 24 25 26 27 28	<b>HINT (sentence)</b> Day 0 Baseline (One month with new replacement HA) Quiet HA+HA	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Missing possible	0-100%
29 30 31 32 33 34 35 36	<b>HINT (word)</b> Day 0 Baseline (One month with new replacement HA) Noise HA right ear	Number of correct words or sentences out of 20 sentences with 5 words pr sentence In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Missing possible	0-100%
37 38 39 40 41 42 43 44	<b>HINT (word)</b> Day 0 Baseline (One month with new replacement HA) Noise HA left ear	Number of correct words or sentences out of 20 sentences with 5 words pr sentence In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Missing possible	0-100%
45 46 47 48 49 50 51 52 53	<b>HINT (word)</b> Day 0 Baseline (One month with new replacement HA) Noise HA+HA	Number of correct words or sentences out of 20 sentences with 5 words pr sentence In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Missing possible	0-100%
54 55 56 57 58 59 60	<b>HINT (sentence)</b> Day 0 Baseline (One month with new replacement HA) Noise HA right ear	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted.	Numeric	Missing possible	0-100%

	Multi-talker babble noise.			
<b>HINT</b> (sentence) Day 0 Baseline (One month with new replacement HA) Noise HA left ear	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Missing possible	0-100%
<b>HINT</b> (sentence) Day 0 Baseline (One month with new replacement HA) Noise HA+HA	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Missing possible	0-100%
<b>SIS</b> free field Auditory Day 0 Baseline (One month with new replacement HA) Quiet HA+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Missing possible	0-100%
<b>SIS</b> free field Auditory Day 0 Baseline (One month with new replacement HA) Quiet HA left ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Missing possible	0-100%
<b>SIS</b> free field Auditory Day 0 Baseline (One month with new replacement HA) Noise HA+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Missing possible	0-100%
<b>SIS</b> free field Auditory Day 0 Baseline (One month with new replacement HA) Noise HA right ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Missing possible	0-100%
<b>SIS</b> free field Auditory Day 0 Baseline (One month with new replacement HA)	Speech identification score in Denmark is percentage correct words out of 25 words.	Numeric	Missing possible	0-100%

Noise HA left ear	Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.			
SIS free field Audio-visual Day 0 Baseline (One month with new replacement HA) Quiet HA+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Missing possible	0-100%
SIS free field Audio-visual Day 0 Baseline (One month with new replacement HA) Quiet HA right ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Missing possible	0-100%
SIS free field Audio-visual Day 0 Baseline (One month with new replacement HA) Quiet HA left ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Missing possible	0-100%
SIS free field Audio-visual Day 0 Baseline (One month with new replacement HA) Noise HA+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Missing possible	0-100%
SIS free field Audio-visual Day 0 Baseline (One month with new replacement HA) Noise HA right ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Missing possible	0-100%
SIS free field Audio-visual Day 0 Baseline (One month with new replacement HA) Noise HA left ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Missing possible	0-100%

	spectrum representing a real life “babble” noise.			
<b>Peak pupil dilation (PPD)</b> Day 0 Baseline (One month with new replacement HA) Quiet HA+HA	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at +10dB SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Missing possible	0-1
<b>Peak pupil dilation (PPD)</b> Day 0 Baseline (One month with new replacement HA) Noise HA+HA	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at +10dB SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Missing possible	0-1
<b>Pupil Peaktime</b> Day 0 Baseline (One month with new replacement HA) Quiet HA+HA	The time it takes for the pupil to reach peak dilation. HINT sentence presented at +10dB SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Missing possible	0-10sec
<b>Pupil Peaktime</b> Day 0 Baseline (One month with new replacement HA) Noise HA+HA	The time it takes for the pupil to reach peak dilation. HINT sentence presented at +10dB SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Missing possible	0-10sec
<b>NCIQ</b> Basic sound Day 0 Baseline (One month with new replacement HA)	Questionnaire	numeric	Missing possible	0-100
<b>NCIQ</b> Advanced Sound Day 0 Baseline (One month with new replacement HA)	Questionnaire	numeric	Missing possible	0-100



(Total of 4 months with new replacement HA) Quiet HA left ear	with 5 words pr sentence			
<b>HINT</b> (word) 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet HA+HA	Number of correct words or sentences out of 20 sentences with 5 words pr sentence	Numeric	Missing possible	0-100%
<b>HINT</b> (sentence) 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet HA right ear	Number of correct sentences. (20 sentences in a HINT)	Numeric	Missing possible	0-100%
<b>HINT</b> (sentence) 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet HA left ear	Number of correct sentences. (20 sentences in a HINT)	Numeric	Missing possible	0-100%
<b>HINT</b> (sentence) 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet HA+HA	Number of correct sentences. (20 sentences in a HINT)	Numeric	Missing possible	0-100%
<b>HINT</b> (word) 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA right ear	Number of correct words or sentences out of 20 sentences with 5 words pr sentence	Numeric	Missing possible	0-100%
<b>HINT</b> (word) 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA left ear	Number of correct words or sentences out of 20 sentences with 5 words pr sentence	Numeric	Missing possible	0-100%
<b>HINT</b> (word) 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA+HA	Number of correct words or sentences out of 20 sentences with 5 words pr sentence	Numeric	Missing possible	0-100%
<b>HINT</b> (sentence) 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA right ear	Number of correct sentences. (20 sentences in a HINT)	Numeric	Missing possible	0-100%
<b>HINT</b> (sentence) 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA left ear	Number of correct sentences. (20 sentences in a HINT)	Numeric	Missing possible	0-100%
<b>HINT</b> (sentence) 3 months	Number of correct sentences.	Numeric	Missing possible	0-100%



Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA+HA	(20 sentences in a HINT)			
<b>SIS</b> free field Auditory 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet HA+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB.	Numeric	Missing possible	0-100%
<b>SIS</b> free field Auditory 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet HA right ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB.	Numeric	Missing possible	0-100%
<b>SIS</b> free field Auditory 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet HA left ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Missing possible	0-100%
<b>SIS</b> free field Auditory 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Missing possible	0-100%
<b>SIS</b> free field Auditory 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA right ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Missing possible	0-100%
<b>SIS</b> free field Auditory 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA left ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Missing possible	0-100%

1 2 3 4 5 6 7 8 9 10 11	<b>SIS</b> Headphones Auditory 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet	Speech identification score in Denmark is percentage correct words out of 25 words. Comfort speech level. Each ear is tested unaided separately.	Numeric	Missing possible	0-100%
12 13 14 15 16 17 18 19 20 21 22	<b>SIS</b> Headphones Auditory 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise	Speech identification score in Denmark is percentage correct words out of 25 words. Comfort speech level. Each ear is tested unaided separately. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life “babble” noise.	Numeric	Missing possible	0-100%
23 24 25 26 27 28	<b>SIS</b> free field Audio-visual 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet HA+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB .	Numeric	Missing possible	0-100%
29 30 31 32 33 34	<b>SIS</b> free field Audio-visual 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet HA right ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB .	Numeric	Missing possible	0-100%
35 36 37 38 39 40	<b>SIS</b> free field Audio-visual 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet HA left ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB .	Numeric	Missing possible	0-100%
41 42 43 44 45 46 47 48 49 50	<b>SIS</b> free field Audio-visual 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65db and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life “babble” noise.	Numeric	Missing possible	0-100%
51 52 53 54 55 56 57 58 59 60	<b>SIS</b> free field Audio-visual 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA right ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65db and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing	Numeric	Missing possible	0-100%

	a real life “babble” noise.			
<b>SIS free field</b> Audio-visual 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA left ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life “babble” noise.	Numeric	Missing possible	0-100%
<b>Peak pupil dilation (PPD)</b> 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet HA+HA	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Missing possible	0-1
<b>Peak pupil dilation (PPD)</b> 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA+HA	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Missing possible	0-1
<b>Pupil Peaktime</b> 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet HA+HA	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Missing possible	0-10sec
<b>Pupil Peaktime</b> 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA+HA	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses	Numeric	Missing possible	0-10sec

	Measurement & analysis tools			
<b>NCIQ</b> Basic sound 3 months Follow-up with new HA (Total of 4 months with new replacement HA)	Questionnaire	numeric	Missing possible	0-100
<b>NCIQ</b> Advanced Sound 3 months Follow-up with new HA (Total of 4 months with new replacement HA)	Questionnaire	numeric	Missing possible	0-100
<b>NCIQ</b> Speech production 3 months Follow-up with new HA (Total of 4 months with new replacement HA)	Questionnaire	numeric	Missing possible	0-100
<b>NCIQ</b> Self-esteem 3 months Follow-up with new HA (Total of 4 months with new replacement HA)	Questionnaire	numeric	Missing possible	0-100
<b>NCIQ</b> Activity limitation 3 months Follow-up with new HA (Total of 4 months with new replacement HA)	Questionnaire	numeric	Missing possible	0-100
<b>NCIQ</b> Social interaction 3 months Follow-up with new HA (Total of 4 months with new replacement HA)	Questionnaire	numeric	Missing possible	0-100
<b>NCIQ</b> Total 3 months Follow-up with new HA (Total of 4 months with new replacement HA)	Questionnaire	numeric	Missing possible	0-100
<b>SSQ</b> Spatial hearing 3 months Follow-up with new HA (Total of 4 months with new replacement HA)	Questionnaire	numeric	Missing possible	0-100
<b>SSQ</b> Hearing quality 3 months Follow-up with new HA (Total of 4 months with new replacement HA)	Questionnaire	numeric	Missing possible	0-100
<b>SSQ</b> Total 3 months Follow-up with new HA (Total of 4 months with new replacement HA)	Questionnaire	numeric	Missing possible	0-100
<b>THI</b> 3 months Follow-up with new HA (Total of 4 months with new replacement HA)	Questionnaire	numeric	Missing possible	0-100

<b>DHI</b> 3 months Follow-up with new HA (Total of 4 months with new replacement HA)	Questionnaire	Numeric	Missing possible	0-100
<b>After CI surgery</b>				
<b>Variable name</b>	<b>Content</b>	<b>Datatype</b>	<b>Missing</b>	<b>Excepted range (numeric data)</b>
<b>TRESHOLDS</b> CI activation day	The patient can be tested at frequencies from 125 Hz up to 8 kHz. Tresholds is tested with headphones and , each ear is tested separately, unaided. The masker is only added when there is a air bone gap >10dB at puretone audiometry	Numeric	Missing possible	0 to 120 db HL
<b>PTA</b> CI activation day	The patient can be tested at frequencies from 125 Hz up to 8 kHz. In free field. In best aided condition. No stimuli.	Numeric	Missing possible	0 to 120 db HL
<b>TRESHOLDS</b> 3 months post bimodal CI+HA-fitting	The patient can be tested at frequencies from 125 Hz up to 8 kHz. Tresholds is tested with headphones and , each ear is tested separately, unaided. The masker is only added when there is a air bone gap >10dB at puretone audiometry	Numeric	Missing possible	0 to 120 db HL
<b>PTA</b> 3 months post bimodal CI+HA - fitting	The patient can be tested at frequencies from 125 Hz up to 8 kHz. In free field. In best aided condition. No stimuli.	Numeric	Missing possible	0 to 120 db HL
<b>TRESHOLDS</b> 6 months post bimodal CI+HA - fitting	The patient can be tested at frequencies from 125 Hz up to 8 kHz.	Numeric	Missing possible	0 to 120 db HL

	Treshholds is tested with headphones and , each ear is tested separately, unaided. The masker is only added when there is a air bone gap >10dB at puretone audiometry			
<b>PTA</b> 6 months post bimodal CI+HA - fitting	The patient can be tested at frequencies from 125 Hz up to 8 kHz. In free field. In best aided condition. No stimuli.	Numeric	Missing possible	0 to 120 db HL
<b>TRESHOLDS</b> 12 months post bimodal CI+HA - fitting	The patient can be tested at frequencies from 125 Hz up to 8 kHz. Treshholds is tested with headphones and , each ear is tested separately, unaided. The masker is only added when there is a air bone gap >10dB at puretone audiometry	Numeric	Missing possible	0 to 120 db HL
<b>PTA</b> 12 months post bimodal CI+HA - fitting	The patient can be tested at frequencies from 125 Hz up to 8 kHz. In free field. In best aided condition. No stimuli.	Numeric	Missing possible	0 to 120 db HL
<b>HINT (word)</b> Post-surgery 3 months after fitting Quiet CI alone	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 6 months after fitting Quiet CI alone	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 12 months after fitting Quiet CI alone	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 3 months after fitting Quiet CI alone	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery	Number of correct sentences.	Numeric	Possible	0-100%

6 months after fitting Quiet CI alone	(20 sentences in a HINT) In free field. Speech level at 65dB HL.			
<b>HINT (sentence)</b> Post-surgery 12 month after fitting Quiet CI alone	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 3 months after fitting Quiet HA alone	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 6 months after fitting Quiet HA alone	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 12 months after fitting Quiet HA alone	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 3 months after fitting Quiet HA alone	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 6 months after fitting Quiet HA alone	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 12 months after fitting Quiet HA alone	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 3 months after fitting Quiet CI+HA	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 6 months after fitting Quiet CI+HA	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field.	Numeric	Possible	0-100%

	Speech level at 65dB HL.			
<b>HINT (word)</b> Post-surgery 12 months after fitting Quiet CI+HA	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 3 months after fitting Quiet CI+HA	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 6 months after fitting Quiet CI+HA	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 12 months after fitting Quiet CI+HA	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 3 months after fitting Noise CI alone	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 6 months after fitting Noise CI alone	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 12 months after fitting Noise CI alone	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 3 months after fitting Noise CI alone	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted.	Numeric	Possible	0-100%



	Multi-talker babble noise.			
<b>HINT (sentence)</b> Post-surgery 6 months after fitting Noise CI alone	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 12 months after fitting Noise CI alone	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 3 months after fitting Noise HA alone	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 6 months after fitting Noise HA alone	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 12 months after fitting Noise HA alone	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 3 months after fitting Noise HA alone	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 6 months after fitting Noise HA alone	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%

	SNR +10 and adapted. Multi-talker babble noise.			
<b>HINT (sentence)</b> Post-surgery 12 months after fitting Noise HA alone	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 3 months after fitting Noise CI+HA	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 6 months after fitting Noise CI+HA	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 12 months after fitting Noise CI+HA	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 3 months after fitting Noise CI+HA	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 6 months after fitting Noise CI+HA	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 12 months after fitting Noise CI+HA	Number of correct sentences. (20 sentences in a HINT) In free field.	Numeric	Possible	0-100%

	Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.			
SIS free field Auditory Post-surgery 3 months after fitting Noise CI only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Possible	0-100%
SIS free field Auditory Post-surgery 6 months after fitting Noise CI only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Possible	0-100%
SIS free field Auditory Post-surgery 12 months after fitting Noise CI only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Possible	0-100%
SIS free field Auditory Post-surgery 3 months after fitting Noise HA only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Possible	0-100%
SIS free field Auditory Post-surgery 6 months after fitting Noise HA only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Possible	0-100%

	a real life “babble” noise.			
SIS free field Auditory Post-surgery 12 months after fitting Noise HA only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life “babble” noise.	Numeric	Possible	0-100%
SIS free field Auditory Post-surgery 3 months after fitting Noise CI+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life “babble” noise.	Numeric	Possible	0-100%
SIS free field Auditory Post-surgery 6 months after fitting Noise CI+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life “babble” noise.	Numeric	Possible	0-100%
SIS free field Auditory Post-surgery 12 months after fitting Noise CI+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life “babble” noise.	Numeric	Possible	0-100%
SIS free field Auditory Post-surgery 3 months after fitting Quiet CI only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
SIS free field Auditory Post-surgery 6 months after fitting Quiet CI only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%

1 2 3 4 5 6 7 8	SIS free field Auditory Post-surgery 12 months after fitting Quiet CI only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
9 10 11 12 13	SIS free field Auditory Post-surgery 3 months after fitting Quiet HA only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
14 15 16 17	SIS free field Auditory Post-surgery 6 months after fitting Quiet HA only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
18 19 20 21 22	SIS free field Auditory Post-surgery 12 months after fitting Quiet HA only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
23 24 25 26 27	SIS free field Auditory Post-surgery 3 months after fitting Quiet CI+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
28 29 30 31	SIS free field Auditory Post-surgery 6 months after fitting Quiet CI+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
32 33 34 35 36	SIS free field Auditory Post-surgery 12 months after fitting Quiet CI+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
37 38 39 40 41	SIS free field Audio-visual Post-surgery 3 months after fitting Quiet CI+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
42 43 44 45	SIS free field Audio-visual Post-surgery 6 months after fitting Quiet CI+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
46 47 48 49 50	SIS free field Audio-visual Post-surgery 12 months after fitting Quiet CI+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
51 52 53 54	SIS free field Audio-visual Post-surgery 3 months after fitting Quiet CI only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
55 56 57 58 59	SIS free field Audio-visual Post-surgery 6 months after fitting Quiet CI only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%

1 2 3 4 5 6 7 8	SIS free field Audio-visual Post-surgery 12 months after fitting Quiet CI only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
9 10 11 12 13	SIS free field Audio-visual Post-surgery 3 months after fitting Quiet HA only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
14 15 16 17	SIS free field Audio-visual Post-surgery 6 months after fitting Quiet HA only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
18 19 20 21 22	SIS free field Audio-visual Post-surgery 12 months after fitting Quiet HA only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
23 24 25 26 27 28 29 30 31 32	SIS free field Audio-visual Post-surgery 3 months after fitting Noise CI+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Possible	0-100%
33 34 35 36 37 38 39 40 41 42	SIS free field Audio-visual Post-surgery 6 months after fitting Noise CI+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Possible	0-100%
43 44 45 46 47 48 49 50 51 52	SIS free field Audio-visual Post-surgery 12 months after fitting Noise CI+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Possible	0-100%
53 54 55 56 57 58 59 60	SIS free field Audio-visual Post-surgery 3 months after fitting Noise CI only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a	Numeric	Possible	0-100%

	speech shaped spectrum representing a real life "babble" noise.			
SIS free field Audio-visual Post-surgery 6 months after fitting Noise CI only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Possible	0-100%
SIS free field Audio-visual Post-surgery 12 months after fitting Noise CI only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Possible	0-100%
SIS free field Audio-visual Post-surgery 3 months after fitting Noise HA only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Possible	0-100%
SIS free field Audio-visual Post-surgery 6 months after fitting Noise HA only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Possible	0-100%
SIS free field Audio-visual Post-surgery 12 months after fitting Noise HA only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Possible	0-100%
Peak pupil dilation (PPD) Post-surgery	PPD is calculated based on the number of pixels. PPD of 0.01	Numeric	Possible	0-1

3 months after fitting Quiet CI only	would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools			
<b>Peak pupil dilation (PPD)</b> Post-surgery 6 months after fitting Quiet CI only	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-1
<b>Peak pupil dilation (PPD)</b> Post-surgery 12 months after fitting Quiet CI only	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-1
<b>Peak pupil dilation (PPD)</b> Post-surgery 3 months after fitting Quiet HA only	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-1
<b>Peak pupil dilation (PPD)</b> Post-surgery 6 months after fitting Quiet HA only	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive	Numeric	Possible	0-1



	SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools			
<b>Peak pupil dilation (PPD)</b> Post-surgery 12 months after fitting Quiet HA only	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-1
<b>Peak pupil dilation (PPD)</b> Post-surgery 3 months after fitting Quiet CI+HA	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-1
<b>Peak pupil dilation (PPD)</b> Post-surgery 6 months after fitting Quiet CI+HA	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-1
<b>Peak pupil dilation (PPD)</b> Post-surgery 12 months after fitting Quiet CI+HA	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-1
<b>Peak pupil dilation (PPD)</b>	PPD is calculated based on the number	Numeric	Possible	0-1

<p>Post-surgery 3 months after fitting Noise CI only</p>	<p>of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement &amp; analysis tools</p>			
<p><b>Peak pupil dilation (PPD)</b> Post-surgery 6 months after fitting Noise CI only</p>	<p>PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement &amp; analysis tools</p>	<p>Numeric</p>	<p>Possible</p>	<p>0-1</p>
<p><b>Peak pupil dilation (PPD)</b> Post-surgery 12 months after fitting Noise CI only</p>	<p>PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement &amp; analysis tools</p>	<p>Numeric</p>	<p>Possible</p>	<p>0-1</p>
<p><b>Peak pupil dilation (PPD)</b> Post-surgery 3 months after fitting Noise HA only</p>	<p>PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement &amp; analysis tools</p>	<p>Numeric</p>	<p>Possible</p>	<p>0-1</p>
<p><b>Peak pupil dilation (PPD)</b> Post-surgery 6 months after fitting Noise HA only</p>	<p>PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive</p>	<p>Numeric</p>	<p>Possible</p>	<p>0-1</p>

	SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools			
<b>Peak pupil dilation (PPD)</b> Post-surgery 12 months after fitting Noise HA only	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-1
<b>Peak pupil dilation (PPD)</b> Post-surgery 3 months after fitting Noise CI+HA	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-1
<b>Peak pupil dilation (PPD)</b> Post-surgery 6 months after fitting Noise CI+HA	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-1
<b>Peak pupil dilation (PPD)</b> Post-surgery 12 months after fitting Noise CI+HA	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-1

<p><b>Pupil Peaktime</b> Post-surgery 3 months after fitting Quiet CI only</p>	<p>The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement &amp; analysis tools</p>	<p>Numeric</p>	<p>Possible</p>	<p>0-10sec</p>
<p><b>Pupil Peaktime</b> Post-surgery 6 months after fitting Quiet CI only</p>	<p>The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement &amp; analysis tools</p>	<p>Numeric</p>	<p>Possible</p>	<p>0-10sec</p>
<p><b>Pupil Peaktime</b> Post-surgery 12 months after fitting Quiet CI only</p>	<p>The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement &amp; analysis tools</p>	<p>Numeric</p>	<p>Possible</p>	<p>0-10sec</p>
<p><b>Pupil Peaktime</b> Post-surgery 3 months after fitting Quiet HA only</p>	<p>The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement &amp; analysis tools</p>	<p>Numeric</p>	<p>Possible</p>	<p>0-10sec</p>
<p><b>Pupil Peaktime</b> Post-surgery 6 months after fitting Quiet HA only</p>	<p>The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement &amp; analysis tools</p>	<p>Numeric</p>	<p>Possible</p>	<p>0-10sec</p>
<p><b>Pupil Peaktime</b> Post-surgery 12 months after fitting Quiet HA only</p>	<p>The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at</p>	<p>Numeric</p>	<p>Possible</p>	<p>0-10sec</p>

	+10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools			
<b>Pupil Peaktime</b> Post-surgery 3 months after fitting Quiet CI+HA	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-10sec
<b>Pupil Peaktime</b> Post-surgery 6 months after fitting Quiet CI+HA	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-10sec
<b>Pupil Peaktime</b> Post-surgery 12 months after fitting Quiet CI+HA	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-10sec
<b>Pupil Peaktime</b> Post-surgery 3 months after fitting Noise CI only	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-10sec
<b>Pupil Peaktime</b> Post-surgery 6 months after fitting Noise CI only	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-10sec

1 2 3 4 5 6 7 8 9 10 11 12 13 14	<b>Pupil Peaktime</b> Post-surgery 12 months after fitting Noise CI only	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-10sec
15 16 17 18 19 20 21 22 23 24	<b>Pupil Peaktime</b> Post-surgery 3 months after fitting Noise HA only	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-10sec
25 26 27 28 29 30 31 32 33 34	<b>Pupil Peaktime</b> Post-surgery 6 months after fitting Noise HA only	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-10sec
35 36 37 38 39 40 41 42 43 44	<b>Pupil Peaktime</b> Post-surgery 12 months after fitting Noise HA only	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-10sec
45 46 47 48 49 50 51 52 53 54	<b>Pupil Peaktime</b> Post-surgery 3 months after fitting Noise CI+HA	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-10sec
55 56 57 58 59 60	<b>Pupil Peaktime</b> Post-surgery 6 months after fitting Noise CI+HA	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive	Numeric	Possible	0-10sec

	SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools			
<b>Pupil Peaktime</b> Post-surgery 12 months after fitting Noise CI+HA	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-10sec
<b>NCIQ</b> Basic sound Post-surgery 3 months after fitting	Questionnaire	numeric	Possible	0-100
<b>NCIQ</b> Advanced Sound Post-surgery 3 months after fitting	Questionnaire	numeric	Possible	0-100
<b>NCIQ</b> Speech production Post-surgery 3 months after fitting	Questionnaire	numeric	Possible	0-100
<b>NCIQ</b> Self-esteem Post-surgery 3 months after fitting	Questionnaire	numeric	Possible	0-100
<b>NCIQ</b> Activity limitation Post-surgery 3 months after fitting	Questionnaire	numeric	Possible	0-100
<b>NCIQ</b> Social interaction Post-surgery 3 months after fitting	Questionnaire	numeric	Possible	0-100
<b>NCIQ</b> Total Post-surgery 3 months after fitting	Questionnaire	numeric	Possible	0-100
<b>NCIQ</b> Basic sound Post-surgery 6 months after fitting	Questionnaire	numeric	Possible	0-100
<b>NCIQ</b> Advanced Sound Post-surgery 6 months after fitting	Questionnaire	numeric	Possible	0-100
<b>NCIQ</b> Speech production Post-surgery 6 months after fitting	Questionnaire	numeric	Possible	0-100
<b>NCIQ</b> Self-esteem Post-surgery 6 months after fitting	Questionnaire	numeric	Possible	0-100
<b>NCIQ</b> Activity limitation Post-surgery 6 months after fitting	Questionnaire	numeric	Possible	0-100
<b>NCIQ</b> Social interaction Post-surgery 6 months after fitting	Questionnaire	numeric	Possible	0-100





12 months after fitting				
<b>SSQ</b> Hearing quality Post-surgery 12 months after fitting	Questionnaire	numeric	Possible	0-100
<b>SSQ</b> Total Post-surgery 12 months after fitting	Questionnaire	numeric	Possible	0-100
<b>THI</b> Post-surgery 2 weeks before fitting	Questionnaire	numeric	Possible	0-100
<b>THI</b> Post-surgery 3 months after fitting	Questionnaire	numeric	Possible	0-100
<b>THI</b> Post-surgery 6 months after fitting	Questionnaire	numeric	Possible	0-100
<b>THI</b> Post-surgery 12 months after fitting	Questionnaire	numeric	Possible	0-100
<b>DHI</b> Post-surgery 2 weeks before fitting	Questionnaire	numeric	Possible	0-100
<b>DHI</b> Post-surgery 3 months after fitting	Questionnaire	numeric	Possible	0-100
<b>DHI</b> Post-surgery 6 months after fitting	Questionnaire	numeric	Possible	0-100
<b>DHI</b> Post-surgery 12 months after fitting	Questionnaire	numeric	Possible	0-100



# CONSORT 2010 checklist of information to include when reporting a randomised trial\*

Section/Topic	Item No	Checklist item	Reported on page No
<b>Title and abstract</b>			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	1
<b>Introduction</b>			
Background and objectives	2a	Scientific background and explanation of rationale	3-6
	2b	Specific objectives or hypotheses	5-6
<b>Methods</b>			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	6-10
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	10-12
Participants	4a	Eligibility criteria for participants	10-12
	4b	Settings and locations where the data were collected	
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	12-13
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	13
	6b	Any changes to trial outcomes after the trial commenced, with reasons	
Sample size	7a	How sample size was determined	
	7b	When applicable, explanation of any interim analyses and stopping guidelines	13-15
<b>Randomisation:</b>			
Sequence generation	8a	Method used to generate the random allocation sequence	9-10
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	9-10
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	9-10/14-15
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	

bmjopen-2022-070296 on 29 December 2022. Downloaded from <http://bmjopen.bmj.com/> on April 27, 2024 by guest. Protected by copyright.

1		assessing outcomes) and how	
2	11b	If relevant, description of the similarity of interventions	14-15
3	Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes
4		12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses
5			14-15
6	<b>Results</b>		
7	Participant flow (a	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and
8	diagram is strongly		were analysed for the primary outcome
9	recommended)	13b	For each group, losses and exclusions after randomisation, together with reasons
10	Recruitment	14a	Dates defining the periods of recruitment and follow-up
11		14b	Why the trial ended or was stopped
12	Baseline data	15	A table showing baseline demographic and clinical characteristics for each group
13	Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was
14			by original assigned groups
15	Outcomes and	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its
16	estimation		precision (such as 95% confidence interval)
17		17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended
18	Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing
19			pre-specified from exploratory
20	Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)
21	<b>Discussion</b>		
22	Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses
23	Generalisability	21	Generalisability (external validity, applicability) of the trial findings
24	Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence
25	<b>Other information</b>		
26	Registration	23	Registration number and name of trial registry
27	Protocol	24	Where the full trial protocol can be accessed, if available
28	Funding	25	Sources of funding and other support (such as supply of drugs), role of funders
29			1, 2, 16, 17
30			17

36  
37 \*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also  
38 recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials.  
39 Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).  
40  
41  
42



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist for the ReTrain pilot RCT: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	2,7,17
	2b	All items from the World Health Organization Trial Registration Data Set	Yes, clinicaltrials.org
Protocol version	3	Date and version identifier	1
Funding	4	Sources and types of financial, material, and other support	17
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1,17
	5b	Name and contact information for the trial sponsor	1,17
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	17
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	17

bmjopen-2022-070296 on 29 December 2022. Downloaded from <http://bmjopen.bmj.com/> on April 27, 2024 by guest. Protected by copyright.

1	<b>Introduction</b>			
2				
3	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	3-6
4				
5				
6		6b	Explanation for choice of comparators	4-5
7				
8	Objectives	7	Specific objectives or hypotheses	6
9				
10	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	7
11				
12				
13				
14	<b>Methods: Participants, interventions, and outcomes</b>			
15				
16	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	1,7,9,10
17				
18				
19	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	7-8
20				
21				
22	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	8-13
23				
24		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	11
25				
26		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	11-12
27				
28				
29		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	12
30				
31				
32	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	9-10,13-15, Appendix A
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	8-9,11-13 Appendix A, Figure 1 and 2
5	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	14, Table 1
8	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	7-10

### Methods: Assignment of interventions (for controlled trials)

#### Allocation:

15	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	9-10
21	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	9-10
25	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	9-10
28	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	9-10
32		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	9-10

### Methods: Data collection, management, and analysis

37	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	13-15, statistical plan(SAP), Data management plan(DMP)
----	-------------------------	-----	--	--

1		18b	Plans to promote participant retention and complete follow-up, including list of any outcomes data to be collected for participants who discontinue or deviate from intervention protocols	13-15, SAP, DMP,
2				
3				
4	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	13-15, SAP, DMP, Appendix A
5				
6				
7				
8	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	13-15, SAP
9				
10				
11		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	13-15, SAP
12				
13		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	13-15, SAP
14				
15				
16				
17	<b>Methods: Monitoring</b>			
18				
19	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	17
20				
21				
22				
23				
24				
25		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	n/a
26				
27				
28	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	13-15, SAP
29				
30				
31	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	n/a
32				
33				
34				
35	<b>Ethics and dissemination</b>			
36				
37	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	2,7,16
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	13-15, SAP
5	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	2,9,11,16
8		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	n/a
11	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	2,9,11,16
15	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	17
18	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	17,MAP
21	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	Consent form
24	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, health care professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	17
29		31b	Authorship eligibility guidelines and any intended use of professional writers	17
31		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	MAP
33	<b>Appendices</b>			
35	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	As online supplementary file
38	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a



1 \*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.  
2 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons  
3 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

For peer review only

bmjopen-2022-0720296 on 29 December 2022. Downloaded from <http://bmjopen.bmj.com/> on April 27, 2024 by guest. Protected by copyright.

# BMJ Open

## A Study Protocol for a Randomised Controlled Trial Evaluating the Benefits from Bimodal Solution with Cochlear Implant and Hearing Aid vs. Bilateral Hearing Aids in Patients with Asymmetric Speech Identification Scores.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-070296.R1
Article Type:	Protocol
Date Submitted by the Author:	13-Dec-2022
Complete List of Authors:	Jakobsen, Yeliz; Odense University Hospital, Head & Neck Surgery and Audiology; Odense University Hospital Christensen Andersen, Lou-Ann; Vejle Hospital, Department of Ophthalmology Schmidt, Jesper; Odense University Hospital, Department of Audiology; Odense University Hospital, Department of Oto-Rhino-Laryngology
<b>Primary Subject Heading</b>:	Ear, nose and throat/otolaryngology
Secondary Subject Heading:	Evidence based practice, Surgery, Communication, Research methods
Keywords:	Audiology < OTOLARYNGOLOGY, Speech pathology < OTOLARYNGOLOGY, Adult otolaryngology < OTOLARYNGOLOGY

SCHOLARONE™  
Manuscripts

# A Study Protocol for a Randomised Controlled Trial Evaluating the Benefits from Bimodal Solution with Cochlear Implant and Hearing Aid vs. Bilateral Hearing Aids in Patients with Asymmetric Speech Identification Scores.

Yeliz Jakobsen<sup>1,2\*</sup>, Lou-Ann Christensen Andersen<sup>3</sup>, Jesper Hvass Schmidt<sup>1,2</sup>

## Affiliation

<sup>1</sup> Research Unit for ORL – Head & Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark; University of Southern Denmark, Odense, Denmark

<sup>2</sup> OPEN, Odense Patient data Explorative Network, Odense University Hospital, Odense, Denmark.

<sup>3</sup>Department of Ophthalmology, Lillebaelt Hospital, Vejle Hospital.

\*Correspondence to Dr. Yeliz Jakobsen; [Yeliz.jakobsen@rsyd.dk](mailto:Yeliz.jakobsen@rsyd.dk)

Date: Friday, 9<sup>th</sup> December 2022

Version: 4

## Abstract

### Introduction

Cochlear implant (CI) and hearing aid (HA) in a bimodal solution (CI + HA) is compared to bilateral HAs (HA +HA) to test if the bimodal solution result in better speech intelligibility and self-reported quality of life.

### Methods and Analysis

This randomised controlled trial (RCT) is conducted in Odense University Hospital, Denmark.

Sixty adult bilateral HA users referred for CI surgery is enrolled if eligible and undergo:

audiometry, speech perception in noise (HINT: Hearing in Noise Test), Speech Identification

Scores (SIS) and video head impulse test (v-HIT). All participants will receive new

replacement HAs. After one month they will be randomly assigned (1:1) to the intervention

group (CI+HA) or to the delayed intervention control group (HA+HA). The intervention group

(CI+HA) will receive a CI on the ear with a poorer speech recognition score and continue

1  
2  
3  
4 32 using the HA on the other ear. The control group (HA+HA) will receive a CI after a total of 4  
5  
6  
7 33 months of bilateral HA use.  
8  
9 34 The primary outcome measures are Speech intelligibility measured objectively with HINT  
10  
11 35 (sentences in noise) and DANTALE I (words) and subjectively with the Speech, Spatial and  
12  
13 36 Qualities of Hearing scale questionnaire (SSQ-12). Secondary outcomes are patient reported  
14  
15  
16 37 Health-Related Quality of Life (HRQoL) scores assessed with the Nijmegen Cochlear Implant  
17  
18 38 Questionnaire (NCIQ), the Tinnitus Handicap Inventory (THI) and Dizziness Handicap  
19  
20 39 Inventory (DHI). Third outcome is listening effort assessed with pupil dilation during HINT  
21  
22  
23 40 In conclusion, the purpose is to improve clinical decision-making for CI candidacy and  
24  
25 41 optimize bimodal solutions.  
26  
27  
28 42

## 30 43 Ethics and Dissemination

31  
32  
33 44 This study protocol was approved by the Ethics Committee Southern Denmark project ID S-  
34  
35 45 20200074G. All participants are required to sign an informed consent form.  
36  
37 46 This study will be published upon completion in a peer-reviewed publications and scientific  
38  
39  
40 47 conferences.  
41  
42 48

43  
44  
45 49 Trial Registration Number: NCT04919928 (ClinicalTrials.gov)  
46  
47 50  
48  
49 51  
50  
51 52  
52  
53 53  
54  
55 54  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 55 **Strengths and Limitations of This Study**

- The study uses comprehensive measures of self-reported outcomes as well as objective tests of speech intelligibility.
- Listening effort controlled with pupillometry during objective tests of speech intelligibility.
- Open label RCT (blinding is not possible due to visibility of the CI).
- Possible large drop rates if new HAs improve speech intelligibility to an extent that CI treatment is rejected or postponed.

## 64 **Introduction**

### 65 **Background**

66 Cochlear implants (CIs) have been used to restore hearing in individuals with severe to  
67 profound sensorineural hearing loss. Initially, most patients receiving a cochlear implant were  
68 profoundly deaf in both ears. (1, 2) However, recently it has become more common to implant  
69 patients with significant residual hearing in the affected ear, as well as in patients with  
70 asymmetric hearing loss and single-sided deafness, with significant residual hearing or normal  
71 hearing on the contralateral side.(3, 4) A CI in one ear and a HA in the other ear can provide  
72 enhanced hearing performance in patients with asymmetrical hearing.(5, 6) The combination  
73 of CI and HA is referred to as bimodal hearing or bimodal solution.(7)

### 75 **CI Candidacy**

76 In the UK, The National Institute for Health and Care Excellence (NICE) have listed guidelines  
77 for cochlear implantation and recommends that unilateral CI is offered to patients with severe

1  
2  
3  
4 78 to profound deafness who do not receive adequate benefit from acoustic hearing aids. Severe  
5  
6 79 to profound deafness is defined as pure-tone audiometric threshold  $\geq 80$  dB HL at 2 or more  
7  
8  
9 80 frequencies (500 Hz, 1,000 Hz, 2,000 Hz, 3,000 Hz and 4,000 Hz). Another criteria is that SIS<  
10  
11 81 50% in the ear considered for implantation and in best aided condition SIS $\leq$ 60%(8).

12  
13 82 The Danish CI candidacy criteria consists of SIS (without HAs, measured with headphones)  
14  
15  
16 83  $\leq$ 45% and a SIS  $\leq$ 65% (in best aided condition) in the ear considered for implantation using  
17  
18 84 DANTALE I monosyllabic word-lists.(9) Additional testing to evaluate speech understanding  
19  
20 85 is assessed by HINT.(10, 11)

21  
22  
23 86 The recommendation for a CI might be less clear for patients with asymmetric hearing  
24  
25 87 because they may not fall into the traditional referral criteria but would likely benefit from a  
26  
27  
28 88 CI. It is therefore necessary to establish more evidence to support the effectiveness of bimodal  
29  
30 89 CI+HA versus HAs in patients with asymmetric hearing.

31  
32 90  
33  
34

### 35 91 Bimodal Solution vs. Bilateral HAs

36  
37 92 Normal hearing listeners (NH) benefit from listening with two ears, which help them  
38  
39  
40 93 understand speech in noise and identify sound location.

41  
42 94 Benefits from listening with two ears include: head shadow effect, binaural summation,  
43  
44 95 binaural squelch, localization and spatial release from masking.(12-15)

45  
46 96 Patients with hearing loss often do not have these benefits, and they are often not accessible to  
47  
48  
49 97 CI patients. (15)Many bimodal CI and HA users are missing these benefits because the devices  
50  
51 98 are unsynchronized.(16)

52  
53  
54 99 Until now it is unknown when to introduce the bimodal solution and making sure that  
55  
56 100 patients are well-fitted with hearing aids when they are given the candidacy assessment.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

101 The question is if the bimodal benefits are bigger than the bilateral hearing aid condition  
102 when they are well fitted?

103 This study will therefore support and strengthen the preoperative clinical decision to  
104 recommend a bimodal solution with a CI and a HA versus the continuous use of bilateral HAs.  
105 This may offer the patient faster and more effective treatment because delaying the surgery  
106 may not be beneficial.

## 108 Patient-Reported Outcome Measures

109 Benefits of the CI are measured subjectively with Patient-Reported Outcome Measures  
110 (PROMs) as SSQ12, NCIQ, THI and DHI.(17-24)

111  
112 The validity and reproducibility of the Danish version of THI has been reported(24). SSQ12,  
113 DHI, NCIQ have all been translated into Danish and backward translated to English following a  
114 cultural adaption and pilot-testing to ensure correct understanding of the questionnaires.  
115 Test-retest reliability has been assessed as well.(18, 20, 22)

## 117 Listening Effort

118 Patients with CI often experience high levels of listening effort, they often report that  
119 understanding speech causes high levels of increased sustained effort which results in  
120 feelings of fatigue.(25) These feelings may lead patients to withdraw socially due to the  
121 stresses involved in communication even though they may not specifically report difficulties  
122 with speech understanding.(19)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

123 Effort in listeners with NH can be reflected by the relationship between speech intelligibility  
124 and pupil-dilation.(26) Listening effort has been defined as the “Deliberate allocation of  
125 mental resources to overcome obstacles in goal pursuit when carrying out a task” and is the  
126 basis for the Framework for Understanding Effortful Listening (FUEL) model.(27)  
127 Understanding speech in challenging hearing environments results in increased auditory and  
128 cognitive processing which can be observed objectively by measuring the pupil dilation  
129 during speech perception in noise, in a task such as the HINT(28-30)

## 131 **Rationale and Objectives**

132 This randomised controlled trial is designed to improve clinical decision-making for CI  
133 candidacy for patients with asymmetric hearing. It is necessary to establish more evidence to  
134 support the effectiveness and the fitting optimization of bimodal CI+HA versus HAs in patients  
135 with asymmetric hearing.

136 The first objective of the study is to evaluate the subjective (SSQ12) and objective (Hearing In  
137 Noise Test (HINT) which is word and sentence based and DANTALE I, which is monosyllabic  
138 word-based) benefits of a bimodal solution (CI+HA) compared to (HA+HA).

139 The second objective is to compare and evaluate patient self-reported outcomes with NCIQ,  
140 THI and DHI in the intervention group (CI+HA) with the control group (HA+HA).

141 The third objective is to evaluate if listening effort, hypothesized to cause fatigue, can be  
142 measured objectively by HINT with pupillometry.

143 To minimize listening effort and optimize the fitting of bimodal solution the CI fitting and  
144 loudness balancing on individual level will be evaluated.(2, 31, 32)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 147 **Methods and Analysis**

### 148 **Study Design, Ethics and Registration**

149 This study is a prospective randomised controlled trial based on a single centre conducted in  
150 Odense University Hospital, Denmark. The study started 01/02/2022 and is expected to end  
151 30/07/2024. It was successfully registered at ClinicalTrials.gov with registration number:  
152 NCT04919928.

153 This study has been approved at Research Ethics Committee Southern Denmark (Projekt-ID:  
154 S-20200074G) 21<sup>st</sup> August 2020 to 31<sup>st</sup> December 2024.

### 156 **Study Population**

157 Sixty participants with bilateral hearing-loss and asymmetric speech identification scores  
158 referred for CI surgery will be included (Figure 1).

### 160 **Inclusion Criteria**

- 161 • Adults >18 years old.
- 162 • Fluent in Danish, including reading and writing
- 163 • Acquired post-lingual deafness
- 164 • Use of bilateral HAs for at least one year prior to evaluation for cochlear implantation  
165 candidacy. This to ensure, that both ears have received auditive stimulation
- 166 • PTA > 40 dB HL in the ear considered for CI implantation and PTA $\geq$ 40 and  $\leq$  70dB HL in  
167 the contralateral ear in best aided condition, in quiet and in noise and in free field.

- 1  
2  
3  
4  
5 168 • SIS <70% in best aided condition in the ear considered for CI implantation and SIS ≥30%  
6  
7 169 and ≤70% in best aided condition in the contralateral ear, in quiet and in noise and in  
8  
9 170 free field.  
10  
11

## 12 171 Exclusion Criteria

- 13  
14  
15 172 • Vestibular loss in the ear not considered for CI implantation  
16  
17 173 • Surgical issues interfering with the site of implantation or anatomical contraindications  
18  
19 such as cochlear malformations, which will be determined using MRI or CT-scans.  
20 174  
21  
22 175 • Auditory nerve lesions.  
23  
24 176 • Central auditory pathway pathologies.  
25  
26  
27 177 • Otosclerosis.  
28  
29 178 • Single sided deafness (SSD).  
30  
31

## 32 179 Setup

33  
34  
35 180 A timeline of the study is shown in (Figure 2).  
36  
37

38 181 All enrolled participants will be tested with audiometry and v-HIT to determine hearing  
39  
40 182 thresholds and status of balance function during the first visit. Patients will receive new  
41  
42 183 replacement HAs. These HAs will be fitted during the second visit and if necessary refitted at  
43  
44 184 every visit in the clinic throughout the study. The baseline measurements will be conducted  
45  
46 185 when both groups have used the new replacement HAs to ensure acclimatisation. The  
47  
48 186 measurements are SIS in quiet and in noise with a signal-to-noise ratio (SNR) of 0dB using  
49  
50 187 DANTALE I speech material. The speech and masking white noise stimulus will be presented at  
51  
52 188 65 dB SPL in the free field. Stimuli will be presented as auditory stimuli only as well as with  
53  
54 189 visual cues, the latter to allow participants to use lipreading cues.  
55  
56  
57  
58  
59 190  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

191 Pupillometry variables are Peak Pupil Dilation (PPD), Mean Pupil Dilation (MPD), peak-time  
192 and standard deviation using HINT (sentences and words).

193 The HINT sentences are presented at a speech level of 65dB and initially an adaptive SNR is  
194 used to identify the SNR of 70% correct word recognition. The SNR at 70% correct word  
195 recognition is used as a fixed SNR during HINT test. The noise is multi-talker babble noise, in  
196 free field, tested in best aided condition. The pupillometry glasses is the Oticon Medical Pupil  
197 Labs glasses.

### 199 Recruitment, Stratification, Randomisation and Allocation

200 All eligible participants will sign a written, informed consent (supplementary file 1) in clinic  
201 after receiving verbal and written study information in Danish. The Danish consent form is  
202 available online at the Odense University Hospital Research Unit website.(33)

203 To ensure acclimatisation, participants will receive new replacement HAs fitted with the  
204 National Acoustic Laboratories (NAL) -non-linear (NL)2 fitting algorithm one month before  
205 the experiment.

206 They will then undergo stratification, depending on the hearing thresholds. One group will  
207 consist of participants with PTA  $\geq$  70dB HL; and the other group will consist of subjects with  
208 PTA  $\leq$  70dB HL and  $\geq$  40 dB HL according to the inclusion criteria. The reason for this  
209 stratification is because pre-operative hearing thresholds may affect the measured outcomes  
210 in the study. Stratification ensures that both the intervention group and the control group will  
211 have an equal distribution of patients with profound hearing loss on the ear considered for  
212 implantation.

213

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

214 Then the participants will be randomly allocated into two groups: the intervention group  
215 (CI+HA) and the control group (HA+HA) according to 1:1 ratio using a blocked randomisation  
216 with randomly varying block size (4 or 6).

217 This randomisation will be accomplished using a computer-generated random sequence in  
218 Research Electronic Data Capture (REDCap), hosted by Odense Patient Explorative Network  
219 (OPEN) in the Region of Southern Denmark and developed by Vanderbilt University,  
220 Nashville, Tennessee, United States.(34)  
221 REDCap will also be used to send out the questionnaires to the participants' online mailbox  
222 (called Eboks in Denmark) throughout the study (see timeline (Figure 2)) and automatically  
223 save the data.

224 Participants will have the opportunity to return to their original HAs if they prefer to do so  
225 after one-month of acclimatisation.

### 227 Control Group

228 Thirty patients, who will be age-matched, randomised and allocated to the control group  
229 HA+HA will continue the use of the new replacement HAs for another three months (total four  
230 months of new replacement HA+HA use), serving as the delayed intervention control group.

### 232 Intervention Group

233 Thirty patients, who will be age-matched, randomised and allocated to the intervention group  
234 CI+HA will undergo surgery as soon as possible after the HA acclimatisation period.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 237 HA Fitting

238 The participant will receive either Phonak (Phonak Link M) or GN (ReSound LiNX Quattro or  
239 Resound ENZO Q) based on their personal preference. Both these HA models can be fitted  
240 with a CI by Advanced Bionics and Cochlear, respectively.

241 The HAs will be fitted according to NAL-NL2 procedures prescriptive fitting formula, which  
242 optimizes audibility in the bimodal solution(2) and will be verified with REM (Real Ear  
243 Measurement) to ensure that the HA is providing adequate gain and then further adjusted for  
244 comfort based on patient feedback.(35)

245 The new HAs will be prescribed to the patients free of charge and future service will also be  
246 free of charge.

247 Participants can drop out of the study if they do not want CI surgery. Collected data will be  
248 analysed if the patient still consents.

249

## 250 CI fitting

251 The CI will be selected depending on the participant's HA selection; that is, the CI that is  
252 compatible with the HA will be selected in order to ensure the most optimal bimodal fitting.

253 One-month post-surgery, the CI will be activated according to the settings and stimulation  
254 strategy based on patient's feedback. The CI will then be fitted with the HA according to the  
255 bimodal fitting formula allowing the HA to keep the NAL-NL2 fitting along with the wireless  
256 connection with the CI. (36, 37)

257 Patients hearing thresholds will be tested on CI activation day. The residual hearing will not  
258 be stimulated in this study.

259

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

260 All participants are offered standard rehabilitation with a speech therapist, including three  
261 visits a week up to 10 weeks following the initial fitting.

262 The training focuses on learning to identify different sounds from the environment and word  
263 discrimination.

264 The new CI will also be prescribed to the patients free of charge and future service will be free  
265 of charge as well.

266

### 267 Loudness Balancing

268 At 3- months follow-up the post-surgery complications will be evaluated and the levels in the  
269 CI will be adjusted if necessary.

270 In the loudness balancing procedure, the patient will have both the hearing aid and CI  
271 activated and at the 6-month follow-up, when the CI mapping levels are stable, patients will  
272 be randomised and assigned to one of three bimodal fitting groups:

273 Group A) will not complete any specific loudness balancing procedures, CI and HA will be  
274 fitted based on individual feedback from the patient.

275 Group B) will be fitted/finetuned using a bimodal loudness balancing task at a medium input  
276 level and adjusted based on the patient feedback. The audiologist will present a mid-level  
277 sound (approx. 55dB SPL (sound pressure level)) at the center-speaker.

278 Group C) will be fitted/finetuned using a bimodal loudness balancing task as group B but the  
279 audiologist will play three levels and adjust the gain for three input levels (soft, medium, and  
280 loud) according to the patient feedback.

281 For both groups B and C, the patient will be given a 'Bimodal Fusion' illustration (see Figure 3)  
282 and asked to provide feedback about the location of the sound by tracing over the line of the

1  
2  
3  
4 283 head. The HA gain will be adjusted using the bimodal adjustment option until the patient  
5  
6  
7 284 reports that the sounds are perceived at the center of the head.(24)

8  
9 285

10  
11  
12 286 **Primary Outcome**

13  
14 287 Primary outcomes are Speech intelligibility scores measured objectively with HINT  
15  
16 288 (sentences and words) and DANTALE I and subjectively with Speech, Spatial and Qualities of  
17  
18  
19 289 Hearing scale (SSQ-12). (9, 10, 22)

20  
21 290

22  
23  
24 291 **Secondary Outcome**

25  
26 292 Patient reported outcomes scores assessed with the Nijmegen Cochlear Implant  
27  
28  
29 293 Questionnaire (NCIQ), The Tinnitus Handicap Inventory (THI) and Dizziness Handicap  
30  
31 294 Inventory (DHI). (18, 20, 24)

32  
33 295

34  
35  
36 296 **Third Outcome**

37  
38 297 Listening effort assessed with pupil dilation with HINT.(10)

39  
40  
41 298

42  
43  
44 299 **Statistics**

45  
46 300 **Power calculation**

47  
48  
49 301 Power calculations with a power of 0.8 with a significance level of 0.05 have been made with  
50  
51  
52 302 STATA IC-15 using standard deviations for the HINT test and expected effect size (38) the  
53  
54 303 NCIQ(18), and the SSQ (internal communication with BEAR (Better Hearing Rehabilitation)  
55  
56 304 study on hearing aid use in Denmark) (Table 1). An estimated within participant standard  
57  
58  
59 305 deviation from the BEAR study of 1,9 in an HA population using the SSQ-12 is used to calculate  
60

the sample size. A difference of 1,4 will require 30 participants in each arm. The effect size is expected to be larger in the CI group which will lower the number of required subjects even further.

Based on this, 30 participants must be enrolled in each arm. Additional six patients (20%) in each arm will be enrolled in the study to account for dropouts.

Test	SD pre	SD post	Expected difference between the two treatment arms	Minimum required group size
1. HINT	6.3%	6.3%	5%	26
2. NCIQ - basic sound perception	14.4	23.5	53	4
2. NCIQ	13.4	19.6	34	6
2. NCIQ - speech perception	18.8	17.8	17	20
2.NCIQ Self-esteem	20.1	16.4	22	13
2.NCIQ Activity	23.0	15.9	27	10
2.NCIQ Social Interactions	19.8	14.5	25	9
3. SSQ Total	1.9	1.9	1.4	30

**Table 1:** Power calculations for the desired tests. Estimated within participant standard deviations (SD pre and SD post) with expected difference and the calculated required group size.

Detailed statistics is presented in the Statistical Analysis Plan (SAP) (supplementary file 2)

## Definition of Analysis Sets

Strategy for intention to treat analysis with incomplete observations.(39)

1. Attempt to follow-up on all randomised participants, even if they withdraw from allocated treatment.
2. Perform a main analysis of all observed data that are valid under a plausible assumption about the missing data.
3. Perform sensitivity analyses to explore the effect of deviations from the assumption made in the main analysis.
4. Account for all randomised participants, at least in the sensitivity analyses.



1  
2  
3  
4 325

5  
6  
7  
8 326 **Analysis specification**

9  
10  
11 327 A constrained linear mixed model is used to analyse the outcome.

12  
13 328 The model will include randomisation group (CI+HA / HA+HA) and time (baseline/follow-up)  
14  
15 329 and their interaction as fixed effects along with the threshold strata that were used in stratifying  
16  
17  
18 330 the randomisation. The model is constrained so that the mean at baseline agrees across the two  
19  
20 331 treatment groups adjusted for threshold stratum, which is reasonable due to the randomisation  
21  
22  
23 332 of implant fitting. Patient ID will be included as a random effect to account for the repeated  
24  
25 333 measurements.

26  
27 334 Secondary outcomes will be analysed analogously in a constrained linear mixed model  
28  
29  
30 335 adjusting for randomisation strata. Model validation checks will be undertaken as described  
31  
32 336 above, switching to bootstrapping the standard errors when model assumptions are rejected.

33  
34  
35 337 Covariates such as age and gender will be included in all models.

36  
37  
38 338

39  
40  
41 339 **Sensitivity analysis**

42  
43  
44 340 Inclusion is performed conditional on Pure Tone Average (PTA) (from 0.5 to 4 kHz) PTA > 40  
45  
46 341 dB HL and SIS <50% in the ear considered for CI implantation and <70% in the best-aided  
47  
48  
49 342 condition which may lead to a truncation effect in the distribution of baseline measurements.  
50  
51 343 To address this, an analysis of covariance (ANCOVA) model conditioning on the baseline will be  
52  
53 344 used to obtain a sensitivity analysis estimate for the main outcome.(40)

54  
55  
56 345 The statistical analysis plan is attached as “supplementary file” along with the Data Description  
57  
58 346 listed in Appendix A (supplementary file 3).

59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

347

## **Patient and Public Involvement**

A focus-group interview was established with six cochlear implant patients. The patients commented on their decision to transition from HA to CI. Based on the feedback from the focus group, the research questions were developed.

The patients also reported problems with adjustments of the CI, when meeting the audiologist for CI adjustment controls.

354

## **Ethics and Dissemination**

Ethics approval for the conduct of this study was obtained from the Ethics Committee Southern Denmark, 21<sup>st</sup> August 2020 project ID S-20200074G.

The project is approved by the Danish Data Protection Agency (file no. 20/22868) in Region South Denmark.

All participants are treated according to current clinical standards regardless of the randomised study participation. The participants are volunteers and can at any moment withdraw their participation in the study without affecting their current or future treatment rights.

The Informed Consent form will be found online and it will be signed by all participants willing to participate the study and stored in their electronic journals in Department of Audiology, Odense University Hospital. All patients are given both oral and written information about the study.

368

369

1  
2  
3  
4 370

5  
6  
7 371 **Results**

8  
9 372 Results will be presented at national and international congresses and published in the  
10  
11 373 scientific literature for the attention of professional and scientific audiences on behalf of all  
12  
13 374 study sites and collaborators. A lay summary report will be published for patients and  
14  
15 375 members of the public.  
16  
17  
18

19 376

20  
21  
22 377 **Footnotes**

23  
24 378 **Authors' Contributions:**

25  
26 379 YJ and JHS are involved in the conception of the study. LCA and JHS wrote the grant application and the draft of the  
27  
28 380 manuscript. JHS and YJ designed and revised the draft methodological content. YJ reviewed the manuscript and JHS critiqued  
29  
30 381 it.

31 382 **Funding:**

32  
33 383 This study is funded by William Demant grant no. 19-3470 and Interfond grant no. 33.188

34  
35 384 **Competing Interests:**

36  
37 385 None declared.

38 386 **Contributorship Statement/Acknowledgements:**

39  
40 387 We are very thankful of the academic English editing by Senior Researcher at Oticon Medical Kathleen Faulkner Scalzo and  
41  
42 388 Assistant Professor Lindsey Van Yper.

43 389 We are grateful for the contribution from the patient advisers.

44  
45 390 **Protocol and Registration:**

46  
47 391 This study is registered in ClinicalTrials.gov: NCT04919928

48  
49 392  
50 393 Figure 1: Flowchart

51  
52 394 Figure 2: Timeline

53  
54 395 Figure 3: Diagram for loudness balancing

55  
56 396 **Reference List**

57 397

58  
59  
60

- 1  
2  
3  
4 398 1. Morera C, Manrique M, Ramos A, Garcia-Ibanez L, Cavalle L, Huarte A, et al.  
5 399 Advantages of binaural hearing provided through bimodal stimulation via a cochlear implant  
6 400 and a conventional hearing aid: a 6-month comparative study. *Acta Otolaryngol.*  
8 401 2005;125(6):596-606.
- 9 402 2. Vroegop JL, Goedegebure A, van der Schroeff MP. How to Optimally Fit a Hearing  
10 403 Aid for Bimodal Cochlear Implant Users: A Systematic Review. *Ear Hear.* 2018;39(6):1039-45.
- 11 404 3. Firszt JB, Holden LK, Reeder RM, Cowdrey L, King S. Cochlear implantation in  
12 405 adults with asymmetric hearing loss. *Ear Hear.* 2012;33(4):521-33.
- 13 406 4. van Zon A, Peters JP, Stegeman I, Smit AL, Grolman W. Cochlear implantation for  
14 407 patients with single-sided deafness or asymmetrical hearing loss: a systematic review of the  
15 408 evidence. *Otol Neurotol.* 2015;36(2):209-19.
- 16 409 5. Thompson NJ, Dillon MT, Buss E, Rooth MA, King ER, Bucker AL, et al. Subjective  
17 410 Benefits of Bimodal Listening in Cochlear Implant Recipients with Asymmetric Hearing Loss.  
18 411 *Otolaryngol Head Neck Surg.* 2020;162(6):933-41.
- 19 412 6. Dillon MT, Buss E, Rooth MA, King ER, McCarthy SA, Bucker AL, et al. Cochlear  
20 413 Implantation in Cases of Asymmetric Hearing Loss: Subjective Benefit, Word Recognition, and  
21 414 Spatial Hearing. *Trends Hear.* 2020;24:2331216520945524.
- 22 415 7. van Loon MC, Smits C, Smit CF, Hensen EF, Merkus P. Cochlear Implantation in  
23 416 Adults With Asymmetric Hearing Loss: Benefits of Bimodal Stimulation. *Otol Neurotol.*  
24 417 2017;38(6):e100-e6.
- 25 418 8. The National Institute for Health and Care Excellence (NICE) 2019.
- 26 419 9. Elberling C, Ludvigsen C, Lyregaard PE. DANTALE: a new Danish speech material.  
27 420 *Scand Audiol.* 1989;18(3):169-75.
- 28 421 10. Nielsen JB, Dau T. The Danish hearing in noise test. *Int J Audiol.* 2011;50(3):202-8.
- 29 422 11. Zhang E, Coelho DH. Beyond Sentence Recognition in Quiet for Older Adults:  
30 423 Implications for Cochlear Implant Candidacy. *Otol Neurotol.* 2018;39(8):979-86.
- 31 424 12. Bronkhorst AW, Plomp R. The effect of head-induced interaural time and level  
32 425 differences on speech intelligibility in noise. *J Acoust Soc Am.* 1988;83(4):1508-16.
- 33 426 13. Bronkhorst AW, Plomp R. Binaural speech intelligibility in noise for hearing-  
34 427 impaired listeners. *J Acoust Soc Am.* 1989;86(4):1374-83.
- 35 428 14. Bronkhorst AW, Plomp R. A clinical test for the assessment of binaural speech  
36 429 perception in noise. *Audiology.* 1990;29(5):275-85.
- 37 430 15. Choi SJ, Lee JB, Bahng J, Lee WK, Park CH, Kim HJ, et al. Effect of low frequency on  
38 431 speech performance with bimodal hearing in bilateral severe hearing loss. *Laryngoscope.*  
39 432 2016;126(12):2817-22.
- 40 433 16. Balkenhol T, Wallhäusser-Franke E, Rotter N, Servais JJ. Cochlear Implant and  
41 434 Hearing Aid: Objective Measures of Binaural Benefit. *Front Neurosci.* 2020;14:586119.
- 42 435 17. Devlin NJ AJ. Getting the most of proms: putting health outcomes at the heart of  
43 436 NHS decision-making. London, Kings Fund and Office of Health Economics 2010.
- 44 437 18. Hinderink JB, Krabbe PF, Van Den Broek P. Development and application of a  
45 438 health-related quality-of-life instrument for adults with cochlear implants: the Nijmegen  
46 439 cochlear implant questionnaire. *Otolaryngol Head Neck Surg.* 2000;123(6):756-65.
- 47 440 19. Hughes SE, Hutchings HA, Rapport FL, McMahon CM, Boisvert I. Social  
48 441 Connectedness and Perceived Listening Effort in Adult Cochlear Implant Users: A Grounded  
49 442 Theory to Establish Content Validity for a New Patient-Reported Outcome Measure. *Ear Hear.*  
50 443 2018;39(5):922-34.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

20. Jacobson GP, Newman CW. The development of the Dizziness Handicap Inventory. *Arch Otolaryngol Head Neck Surg.* 1990;116(4):424-7.
21. Mertens G, De Bodt M, Van de Heyning P. Cochlear implantation as a long-term treatment for ipsilateral incapacitating tinnitus in subjects with unilateral hearing loss up to 10 years. *Hear Res.* 2016;331:1-6.
22. Noble W, Jensen NS, Naylor G, Bhullar N, Akeroyd MA. A short form of the Speech, Spatial and Qualities of Hearing scale suitable for clinical use: the SSQ12. *Int J Audiol.* 2013;52(6):409-12.
23. Servais JJ, Hörmann K, Wallhäusser-Franke E. Unilateral Cochlear Implantation Reduces Tinnitus Loudness in Bimodal Hearing: A Prospective Study. *Front Neurol.* 2017;8:60.
24. Zachariae R, Mirz F, Johansen LV, Andersen SE, Bjerring P, Pedersen CB. Reliability and validity of a Danish adaptation of the Tinnitus Handicap Inventory. *Scand Audiol.* 2000;29(1):37-43.
25. Winn MB, Edwards JR, Litovsky RY. The Impact of Auditory Spectral Resolution on Listening Effort Revealed by Pupil Dilation. *Ear Hear.* 2015;36(4):e153-65.
26. Zekveld AA, Kramer SE, Festen JM. Pupil response as an indication of effortful listening: the influence of sentence intelligibility. *Ear Hear.* 2010;31(4):480-90.
27. Pichora-Fuller MK, Kramer SE, Eckert MA, Edwards B, Hornsby BW, Humes LE, et al. Hearing Impairment and Cognitive Energy: The Framework for Understanding Effortful Listening (FUEL). *Ear Hear.* 2016;37 Suppl 1:5s-27s.
28. Ohlenforst B, Zekveld AA, Lunner T, Wendt D, Naylor G, Wang Y, et al. Impact of stimulus-related factors and hearing impairment on listening effort as indicated by pupil dilation. *Hear Res.* 2017;351:68-79.
29. Wendt D, Koelewijn T, Książek P, Kramer SE, Lunner T. Toward a more comprehensive understanding of the impact of masker type and signal-to-noise ratio on the pupillary response while performing a speech-in-noise test. *Hear Res.* 2018;369:67-78.
30. Eckert MA, Teubner-Rhodes S, Vaden KI, Jr. Is Listening in Noise Worth It? The Neurobiology of Speech Recognition in Challenging Listening Conditions. *Ear Hear.* 2016;37 Suppl 1(Suppl 1):101s-10s.
31. Francart T, McDermott HJ. Psychophysics, fitting, and signal processing for combined hearing aid and cochlear implant stimulation. *Ear Hear.* 2013;34(6):685-700.
32. Wang Y, Naylor G, Kramer SE, Zekveld AA, Wendt D, Ohlenforst B, et al. Relations Between Self-Reported Daily-Life Fatigue, Hearing Status, and Pupil Dilation During a Speech Perception in Noise Task. *Ear Hear.* 2018;39(3):573-82.
33. Jakobsen Y, Schmidt JH. Behandling af nedsat hørelse med cochlear implantat (CI) og høreapparat i kombination i forhold til høreapparater alene. 2022. <https://ouh.dk/media/vwihy4wi/deltagerinformation-for-bimodal-med-lodtr%C3%A6kning.pdf> (accessed 21. Aug. 2022).
34. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform.* 2009;42(2):377-81.
35. Digeser FM, Engler M, Hoppe U. Comparison of bimodal benefit for the use of DSL v5.0 and NAL-NL2 in cochlear implant listeners. *Int J Audiol.* 2020;59(5):383-91.
36. Cuda D, Murri A, Mainardi A, Chalupper J. Effectiveness and efficiency of a dedicated bimodal fitting formula. *Audiol Res.* 2019;9(1):219.

- 1  
2  
3  
4 489 37. Stronks HC, Briaire JJ, Frijns JHM. The Temporal Fine Structure of Background  
5 490 Noise Determines the Benefit of Bimodal Hearing for Recognizing Speech. *J Assoc Res*  
6 491 *Otolaryngol.* 2020;21(6):527-44.  
8 492 38. Poissant SF, Bero EM, Busekroos L, Shao W. Determining cochlear implant users'  
9 493 true noise tolerance: use of speech reception threshold in noise testing. *Otol Neurotol.*  
10 494 2014;35(3):414-20.  
11 495 39. White IR, Horton NJ, Carpenter J, Pocock SJ. Strategy for intention to treat analysis  
12 496 in randomised trials with missing outcome data. *Bmj.* 2011;342:d40.  
14 497 40. Liu GF, Lu K, Mogg R, Mallick M, Mehrotra DV. Should baseline be a covariate or  
15 498 dependent variable in analyses of change from baseline in clinical trials? *Stat Med.*  
16 499 2009;28(20):2509-30.

**Figure 1**





Figure 2



<sup>1</sup>Estimating hearing status pre-surgery

<sup>2</sup>Video Head Impulse Test v-HIT: clinical -routine measure.

<sup>3</sup>Hearing in noise test. Quiet and noise. Fixed SNR = +10dB. Free field with HAs


<sup>4</sup>Speech Identification Score: Words and sentences. Auditory and audiovisual. In quiet and in noise.

<sup>5</sup>Peak Pupil Dilation (PPD)

<sup>6</sup>Questionnaires: Speech, Spatial and Qualities-12 (SSQ-12), Nijmegen Cochlear Implant Questionnaire (NCIQ), Tinnitus Handicap Inventory (THI), Dizziness Handicap Inventory (DHI) will all be distributed by using REDCap to participants digital mail-box.

<sup>7</sup>The three groups are described in detail in the protocol.



**Figure 3**

This diagram that will be placed in front of the patient to track that the sound is balanced by indicating where they hear it. A sound will be presented in front of the listener and hearing aid gain is adjusted until the patient hears the sounds 'fused' or that it is coming from the same location/sounds centered. The figure will be used for group B and C. (The diagram is created by YJ)

# Deltagerinformation

-om deltagelse i et videnskabeligt forsøg

## Behandling af nedsat hørelse med cochlear implantat (CI) og høreapparat i kombination i forhold til høreapparater alene.

### Projektets originale titel:

Fordele ved bimodal tilpasning med cochlear implantat og høreapparat sammenlignet med dobbeltsidig høreapparat hos patienter med asymmetrisk taleforståelse: Et kontrolleret lodtrækningsforsøg

Øre-Næse-Halskirurgisk/Høreklubben

Odense Universitetshospital

## Kære deltager

Kære Deltager

Vi vil spørge, om du vil deltage i et videnskabeligt forsøg.

Før du beslutter, om du vil deltage i forsøget, skal du fuldt ud forstå, hvad forsøget går ud på, og hvorfor vi gennemfører forsøget.

Vi vil derfor bede dig om at læse denne deltagerinformation grundigt.

Der er to QR koder i denne deltagerinformation, som beskriver projektet mere kortfattet.

Inden du kan indgå i forsøget, vil du ligeledes modtage mundtlig information af den forsøgsansvarlige læge.

Hvis du beslutter dig for at deltage i forsøget, vil vi bede dig om at underskrive en samtykkeerklæring. Denne samtykkeerklæring giver de forsøgsansvarlige mulighed for at få direkte adgang til relevante oplysninger i din journal for at kunne indsamle data, gennemføre, overvåge og kontrollere forsøget.

De oplysninger, der indsamles fra din journal vil være helbredsoplysninger, tidligere og aktuelle skanninger af forhold omkring øret, oplysninger om evt. øreoperationer og behandling med høreapparater samt resultater af de undersøgelser, vi udfører, og som du tidligere har fået udført omkring hørelse og balancefunktion.

Det vil kun være den forsøgsansvarlige læge og projektkoordinator, der har adgang til din journal i forbindelse med gennemførelse af forsøget. De relevante oplysninger fra din journal registreres i anonymiseret form i en database sammen med de data, der indsamles som en del af forsøget.

Samarbejdspartnere (producenter af måleapparater) har ikke adgang til din journal, men kan dog få adgang til en afgrænset del af data i anonymiseret form, når der opstår et specifikt behov herfor. Det kan f.eks. være relevant, hvis de forsøgsansvarlige får behov for teknisk hjælp i forbindelse med behandling af data. En sådan dataadgang vil kun blive givet, hvis der foreligger en godkendt databehandlaftale mellem virksomheden og Region Syddanmark, der er den dataansvarlige myndighed.

Husk, at du har ret til betænkningstid, før du beslutter, om du vil underskrive samtykkeerklæringen. Det er frivilligt at deltage i forsøget. Du kan når som helst trække dit samtykke tilbage. Det har stor gavn for forskningen at kende årsagen til, at du ikke ønsker at deltage, men du skal naturligvis ikke oplyse årsagen, hvis ikke du ønsker det.

Det vil ikke få konsekvenser for din behandling.

Hvis der er behov for ekstra besøg på Høreklinikken på Odense Universitetshospital i forbindelse med forsøget, vil der blive betalt transportgodtgørelse herfor.

Forsøget er et samarbejde mellem, Øre-næse-hals kirurgisk afdeling og Høreklinikken på Odense Universitetshospital, og Øre-Næse-halskirurgisk og Audiologisk afdeling på Rigshospitalet.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15 På de følgende sider kan du læse, hvad det vil  
16 betyde for dig, hvis du vælger at deltage i  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

På de følgende sider kan du læse, hvad det vil betyde for dig, hvis du vælger at deltage i forsøget.

Afslutningsvist kommer de sider, hvor både du og lægen, der informerer dig, skal skrive under.

## FORMÅL MED FORSØGET

Du er blevet spurgt, om du vil deltage i dette forsøg, fordi du har nedsat hørelse i svær grad og er derfor tilbudt operation med et høreimplantat = cochlear implantat også kaldet et CI, på det dårligst hørende øre.



Formålet med dette forsøg er at undersøge, hvilken behandling, der giver den bedste hørelse for dig som patient.

Alle patienter, der indgår i forsøget, får tilpasset to nye høreapparater, der kan tilpasses med et CI. Høreapparaterne skal man anvende og vænne sig til at bruge i ca. 1 måned.

Herefter trækkes der lod om du udvælges til at få en CI operation på det dårligst hørende øre og fortsætte med at anvende det nye høreapparat på det andet øre eller om du udvælges til at være i den anden gruppe som fortsætter yderligere 3 måneder med begge høreapparater for derefter at tilbydes CI operation.

Formålet er at undersøge om patienter hører bedre med et CI der kan arbejde sammen med et høreapparat sammenlignet med bedst tilpasset høreapparat behandling.



Vi vil undersøge mange aspekter af hørelsen herunder lydopfattelse med høreprøver og tests af taleforståelighed. Desuden vil vi som noget nyt måle på bevægelsen af dine øjne (pupiller), når du gennemfører disse tests. Dette har til formål at undersøge, hvor meget du anstrenger dig for at høre i de forskellige test situationer.

Hvis du bliver så glad for dine nye høreapparater at du ikke længere ønsker en operation med et CI, så får du selvfølgelig lov til at aflyse operationen.

Dette forsøg er vigtigt i forhold at forbedre retningslinjer med henblik på at give en mere præcis vurdering for den enkelte patient i forhold til at operere en patient med nedsat hørelse eller fortsætte behandling med høreapparater.

Alle høreapparater og høreimplantater, der anvendes til forsøget, er godkendte, og de er alle tilgængelige behandlingsmuligheder på klinikker i Danmark, hvor man udfører behandling med høre-implantater

Forsøget har brug for 60 deltagere i alt.

## NYTTE VED FORSØGET

CI er i rivende udvikling, men desværre er en behandling med disse ikke helt uden konsekvenser for dig som patient. En operation med et høreimplantat giver en risiko for at udvikle permanent svimmelhed, forstyrrelser af smagssansen, og påvirkning af ansigtsnerven samt infektion.

Det er ikke altid, at hørelsen forbedres så meget som ønsket ved en behandling med CI. Nogle patienter kan opleve øresusen (tinnitus) efter operationen, mens andre oplever at et CI har behandlet deres tinnitus.

I nogle situationer kan der være fordele ved høreapparatbehandling, frem for behandling med CI eks. hvis man lytter til musik eller når man taler i telefon. Derimod kan et CI give en bedre forståelse af tale i mindre forsamlinger end det opleves med et høreapparat.

Det forventes at alle disse fordele kan opleves med den bimodale løsning (et CI kombineret med et høreapparat).

Stærkt nedsat hørelse forringer livskvaliteten hos de fleste, det er derfor vigtigt, at du som patient kan tilbydes og hjælpes med den behandling, der er den helt rigtige for dig.

En behandling med et CI kan ikke laves om, så derfor er det meget vigtigt, at behandlingen tilbydes på det helt rigtige tidspunkt.

Fordelene ved behandlingen med et CI skal overstige de mulige ulemper for dig som patient.

Dette forsøg vil bidrage til, at sundhedspersonale, der arbejder med hørehæmmede, bliver bedre til at rådgive dig som patient, om det helt rigtige tidspunkt for at få foretaget en operation med et CI. Desuden indeholder forsøget en række andre og nye tests, der vil kunne anvendes til fremtidige patienter, hvis netop disse tests viser sig at kunne hjælpe dig som patient i samarbejde med sundhedspersonalet til at træffe den bedste beslutning for behandlingen af høretab.

Som patient vil man være meget sikker på, at man får et optimalt udbytte af behandlingen, og dette er også afgørende for det sundhedspersonale, der skal rådgive dig. Derfor vil et forsigtighedsprincip ofte gøre, at man i nogle situationer ikke ønsker eller ikke får tilbudt den behandling, der i virkeligheden var den, der kunne forbedre hørelsen og dermed livskvaliteten mest muligt.

Resultaterne af dette forsøg vil rykke ved de behandlingsgrænser, som vi i dag anvender, når vi skal behandle patienter med et svært høretab.

Dette projekt kan bane vej for, at hørehæmmede får bedre hørelse og taleforståelse samt højere livskvalitet.

## **BIVIRKNINGER, RISICI, KOMPLIKATIONER OG ULEMPER**

Du vil som deltager i dette studie få den sædvanlige information om bivirkninger og kendte komplikationer i relation til behandlingen med CI. Denne information findes i den patientfolder, som du har fået udleveret på Høreklinikken

I forbindelse med dette forsøg vil der ikke være bivirkninger, risici eller komplikationer udover dem, som du kan risikere i forbindelse med en behandling med et høreimplantat.

Ulemperne vil være, at halvdelen af deltagerne i dette studie skal vente yderligere 3 mdr. på operationen med CI, da effekten af de nye høreapparater skal afprøves og testes i denne gruppe.

## **PLAN FOR FORSØGET**

Forsøget vil vare lidt over et år fra den dato, hvor du tilbydes behandling med høreimplantat. Du bliver undersøgt min. 4 gange efter operationen, hvilket er fastlagt 1,3,6 og 12 måneder efter operationen. Derudover er der opfølgninger som er standard procedure, når man får et CI.

Undersøgelserne udføres af en læge sammen med en audiolog eller audiologiassistent.

Undersøgelserne omfatter følgende:

Spørgeskemaer, der vil blive sendt til dig forud for undersøgelsestidspunktet.

Forskellige høreprøver af tone-opfattelse og tale forståelighed med og uden høreapparater.

Undersøgelse af din balancefunktion.

Observation af øjne (pupiller) i forbindelse med gennemførelse af test for tale forståelighed.

## **OPLYSNINGER OM ØKONOMISKE FORHOLD**

Forsøget er støttet med en bevilling på 2.798.250 kr. fra William Demant Fonden, der indsættes på forskningskonto på Odense Universitetshospital. Bevillingen er givet som et totalt beløb for hele projektet, og det er ikke afhængt af, hvor mange patienter, der deltager i projektet. Herudover er der en bevilling på 180.000 kr. fra Interfond, der ligeledes indsættes på forskningskonto på Odense Universitetshospital. Forsøget er således støttet med 2.978.250 kr. I alt 2.165.000 kr. er afsat til aflønning af forskere og hjælpepersonale, der er ansat på Odense Universitetshospital i hele projektperioden, og som kan frikøbes helt eller delvist til gennemførelse af projektet. Der er ikke personer tilknyttet forskningsprojektet, som får særskilt honorering ud over den løn, der oppebæres ved ansættelse på Odense Universitetshospital, i forbindelse med gennemførelse af projektet.

Et evt. tilbageværende overskydende støttebeløb efter projektperioden vil blive forsøgt anvendt inden for projektets formål eks. til udgivelse af videre forskningsresultater på baggrund af undersøgelsen eller returneret som ubrugte midler til William Demant Fonden og Interfond.

## KOMPENSATION TIL FORSØGSPERSONER

Du kan som forsøgsperson ikke få betaling for deltagelse i forsøget, da forsøget udføres som en del af de normale besøg på høreklubben, dog gives der transportgodtgørelse efter gældende regler og derudover, hvis der er såfremt der måtte opstå ekstra besøg mhp. flere undersøgelser.

## ADGANG TIL FORSØGSRESULTATER

Du kan som forsøgsperson få oplysninger om forsøgets resultater ved at henvende dig til den forsøgsansvarlige. Resultater vil dog ikke være tilgængelige før tidligst 2 år efter, at du er inkluderet i forsøget. Du vil kunne få resultater af dine egne tests umiddelbart efter de er foretaget, men de samlede forsøgs hovedresultater vil først være tilgængelige, når alle deltagerne i forsøget har gennemført alle tests.

## AFSLUTNING

Vi håber, at du med denne information har fået tilstrækkeligt indblik i, hvad det vil sige at deltage i forsøget, og at du føler dig rustet til at tage beslutningen om din eventuelle deltagelse.

Vi beder dig også om at læse det vedlagte materiale "Forsøgspersoners rettigheder i et sundhedsvidenskabeligt forskningsprojekt".



**KONTAKTPERSONER**

Hvis du vil vide mere, er du meget velkommen til at os.

**PROJEKTKOORDINATOR:**

Læge Yeliz Jakobsen

[Yeliz.jakobsen@rsyd.dk](mailto:Yeliz.jakobsen@rsyd.dk)

Tlf: 65412536

**FORSØGSANSVARLIG LÆGE:**

Jesper Hvass Schmidt overlæge, ph.d.

Øre-næse-hals/Høreklubben afd. F

Odense Universitetshospital

Klinisk lektor, Klinisk Institut

Syddansk Universitet

[Jesper.schmidt@rsyd.dk](mailto:Jesper.schmidt@rsyd.dk)

Tlf: 65412536

**BILAG:**

- ”Forsøgspersonens rettigheder i et sundhedsvidenskabeligt forskningsprojekt”
- Komitesystemets fortrykte samtykkeerklæringer.

## Forsøgspersoners rettigheder i et sundhedsvidenskabeligt forskningsprojekt

Som deltager i et sundhedsvidenskabeligt forskningsprojekt skal du vide, at:

- Din deltagelse i forskningsprojektet er helt frivillig og kun kan ske efter, at du har fået både skriftlig og mundtlig information om forskningsprojektet og underskrevet samtykkeerklæringen.
- Du til enhver tid mundtligt, skriftligt eller ved anden klar tilkendegivelse kan trække dit samtykke til deltagelse tilbage og udtræde af forskningsprojektet. Såfremt du trækker dit samtykke tilbage påvirker dette ikke din ret til nuværende eller fremtidig behandling eller andre rettigheder, som du måtte have.
- Du har ret til at tage et familiemedlem, en ven eller en bekendt med til informations samtalen.
- Du har ret til betænkningstid, før du underskriver samtykkeerklæringen.
- Oplysninger om dine helbredsforhold, øvrige rent private forhold og andre fortrolige oplysninger om dig, som fremkommer i forbindelse med forskningsprojektet, er omfattet af tavshedspligt.
- Behandling af oplysninger om dig, herunder oplysninger i dine blodprøver og væv, sker efter reglerne i databeskyttelsesforordningen, databeskyttelsesloven samt sundhedsloven. Den dataansvarlige i forsøget skal orientere dig nærmere om dine rettigheder efter databeskyttelsesreglerne.
- Der er mulighed for at få aktindsigt i forsøgsprotokoller efter offentlighedslovens bestemmelser. Det vil sige, at du kan få adgang til at se alle papirer vedrørende forsøgets tilrettelæggelse, bortset fra de dele, som indeholder forretningshemmeligheder eller fortrolige oplysninger om andre.
- Der er mulighed for at klage og få erstatning efter reglerne i lov om klage- og erstatningsadgang inden for sundhedsvæsenet. Hvis der under forsøget skulle opstå en skade kan du henvende dig til Patienterstatningen, se nærmere på [www.patienterstatningen.dk](http://www.patienterstatningen.dk)

### De Videnskabsetiske Komiteer for Region Hovedstaden (6 komiteer)

Tlf.: +45 38 66 63 95  
E-mail: [vek@regionh.dk](mailto:vek@regionh.dk)  
Hjemmeside:  
[www.regionh.dk/vek](http://www.regionh.dk/vek)

### Den Videnskabsetiske Komité for Region Sjælland

Tlf.: +45 93 56 60 00  
E-mail: [RVK-sjaelland@regionsjaelland.dk](mailto:RVK-sjaelland@regionsjaelland.dk)  
Hjemmeside:  
<https://www.regionsjaelland.dk/sundhed/forskning/forfagfolk/videnskabsetisk-komite/Sider/default.aspx>

### De Videnskabsetiske Komiteer for Region Syddanmark (2 komiteer)

Tlf.: + 45 76 63 82 21  
E-mail: [komite@rsyd.dk](mailto:komite@rsyd.dk)  
Hjemmeside:  
[www.regionsyddanmark.dk/komite](http://www.regionsyddanmark.dk/komite)

### De Videnskabsetiske Komiteer for Region Midtjylland (2 komiteer)

Tlf.: +45 78 41 01 83  
/ +45 78 41 01 82 / +45 78  
41 01 81  
E-mail: [komite@rm.dk](mailto:komite@rm.dk)  
Hjemmeside:  
[www.komite.rm.dk](http://www.komite.rm.dk)

### Den Videnskabsetiske Komité for

Region Nordjylland Tlf.: +45  
97 64 84 40  
E-mail: [vek@rn.dk](mailto:vek@rn.dk)  
Hjemmeside: [www.rn.dk/vek](http://www.rn.dk/vek)

### National Videnskabsetisk Komité

Tlf.: +45 72 21 68 55  
E-mail: [kontakt@nvk.dk](mailto:kontakt@nvk.dk)  
Hjemmeside: [www.nvk.dk](http://www.nvk.dk)

1  
2  
3 **(S1) Informeret samtykke til deltagelse i et sundhedsvidenskabeligt forskningsprojekt.**  
4

5 **Forskningsprojektets titel:**

6  
7 Behandling af nedsat hørelse med cochlear implantat og høreapparat i kombination i forhold  
8 til høreapparater alene.  
9

10 **Projektets originale titel:** Fordele ved bimodal tilpasning med cochlear implantat og  
11 høreapparat sammenlignet med dobbeltsidig høreapparat hos patienter med asymmetrisk  
12 taleforståelse: Et kontrolleret lodtrækningsforsøg.  
13

14 **Erklæring fra forsøgspersonen:**

15  
16 Jeg har fået skriftlig og mundtlig information og jeg ved nok om formål, metode, fordele og  
17 ulemper til at sige ja til at deltage.  
18

19 Jeg ved, at det er frivilligt at deltage, og at jeg altid kan trække mit samtykke tilbage uden at  
20 miste mine nuværende eller fremtidige rettigheder til behandling.  
21

22 Jeg giver samtykke til, at deltage i forskningsprojektet, og har fået en kopi af dette  
23 samtykkeark samt en kopi af den skriftlige information om projektet til eget brug.  
24  
25

26 Forsøgspersonens navn: \_\_\_\_\_  
27

28  
29 Dato: \_\_\_\_\_ Underskrift: \_\_\_\_\_  
30  
31

32  
33 Ønsker du at blive informeret om forskningsprojektets resultat samt eventuelle konsekvenser  
34 for dig?:  
35

36 Ja \_\_\_\_\_ (sæt x)      Nej \_\_\_\_\_ (sæt x)  
37

38 Ønsker du at blive kontaktet ved fremtidige projekter på Høreklinikken/Øre-næse-hals afd.?:  
39

40 Ja \_\_\_\_\_ (sæt x)      Nej \_\_\_\_\_ (sæt x)  
41  
42

43 **Erklæring fra den, der afgiver information:**

44  
45 Jeg erklærer, at forsøgspersonen har modtaget mundtlig og skriftlig information om forsøget.  
46

47 Efter min overbevisning er der givet tilstrækkelig information til, at der kan træffes  
48 beslutning om deltagelse i forsøget.  
49

50 Navnet på den, der har afgivet information: \_\_\_\_\_  
51  
52

53  
54 Dato: \_\_\_\_\_ Underskrift: \_\_\_\_\_  
55  
56

57 Projektidentifikation: Sagsnummer 20202000-84  
58  
59  
60

## Statistical analysis plan (SAP) for randomised clinical studies.

<b>Project responsible</b> Consultant Jesper Hvass Schmidt and Ph.D. student Yeliz Jakobsen
<b>Title</b> A Study Protocol for a Randomised Controlled Trial Evaluating the Benefits from Bimodal Solution with Cochlear Implant and Hearing Aids vs. Bilateral Hearing Aids in Patients with Asymmetric Speech Identification Scores.
<b>Deadline</b> 30.07.2024
<b>Study design</b> Randomised controlled trial
<b>Samplesize</b> 60 participants
<b>Aim</b> This randomised controlled trial is designed to improve clinical decision-making for CI candidacy for patients with asymmetric hearing. It is necessary to establish more evidence to support the effectiveness and the fitting optimization of bimodal CI+HA versus HAs in patients with asymmetric hearing.

The first objective of the study is to evaluate the subjective (SSQ12) and objective (Hearing In Noise Test (HINT) which is word and sentence based and DANTALE I, which is monosyllabic word-based) benefits of a bimodal solution (CI+HA) compared to (HA+HA). The second objective is to compare and evaluate patient self-reported outcomes with NCIQ, THI and DHI in the intervention group (CI+HA) with the control group (HA+HA). The third objective is to evaluate if listening effort, hypothesized to cause fatigue, can be measured objectively by HINT with pupillometry. To minimize listening effort and optimize the fitting of bimodal solution the CI fitting and loudness balancing on individual level will be evaluated.

### **Hypothesis**

Patients treated with a CI on the poorer hearing ear and a HA to the better hearing ear (CI+HA) in a bimodal solution have increased objective and subjective measured speech intelligibility compared to patients treated with new bilateral replacement hearing aids (HA+HA).

## **2) Data description**

See Appendix A

## **3) The statistical analysis plan (SAP)**

### **Definition of outcome**

Primary Outcome

Primary outcomes are Speech intelligibility scores measured objectively with HINT (sentences and words) and DANTALE I and subjectively with Speech, Spatial and Qualities of Hearing scale (SSQ-12).

#### Secondary Outcome

Patient reported outcomes scores assessed with the Nijmegen Cochlear Implant Questionnaire (NCIQ), The Tinnitus Handicap Inventory (THI) and Dizziness Handicap Inventory (DHI).

#### Third Outcome

Listening effort assessed with pupil dilation with HINT.

#### **Definition of treatment variables**

Treatments are HAs and CI-surgery assigned by randomisation. The primary comparison will be between the CI+HA and HA+HA groups.

#### **Covariates used in analyses**

Stratified randomisation for thresholds of the ear to be implanted.

#### **Definition of effect size/parameter of interest**

Primary effect size:

Objective outcome: Mean difference in HINT in quiet and in noise between intervention group (HA+CI) and control group (HA+HA) at 3, 6 and 12 months follow-up post- bimodal CI+HA-fitting and 3 months post-HA-fitting respectively.

1  
2  
3  
4  
5  
6 Subjective outcome: Mean difference in SSQ-12-scores at 3, 6 and 12 months follow-up  
7  
8 post- bimodal CI+HA-fitting and 3 months post-HA-fitting respectively  
9

### 10 **Definition of Analysis Sets**

11  
12 Strategy for intention to treat analysis with incomplete observations.<sup>1)</sup>

- 13 1. Attempt to follow-up on all randomised participants, even if they withdraw from  
14 allocated treatment.
- 15 2. Perform a main analysis of all observed data that are valid under a plausible  
16 assumption about the missing data.
- 17 3. Perform sensitivity analyses to explore the effect of deviations from the assumption  
18 made in the main analysis.
- 19 4. Account for all randomised participants, at least in the sensitivity analyses.

20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33 1)

34  
35  
36 White, Ian R., Nicholas J. Horton, James Carpenter, and Stuart J. Pocock. 2011. 'Strategy for  
37 Intention to Treat Analysis in Randomised Trials with Missing Outcome Data'. *BMJ* 342  
38  
39 (February): d40. <https://doi.org/10.1136/bmj.d40>.  
40  
41  
42  
43  
44  
45

### 46 **Analysis specification**

47  
48 A constrained linear mixed model is used to analyse the outcome.

49  
50 The model will include randomisation group (CI+HA / HA+HA) and time (baseline/follow-  
51 up) and their interaction as fixed effects along with the threshold strata that were used in  
52 stratifying the randomisation. The model is constrained so that the mean at baseline agrees  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 across the two treatment groups adjusted for threshold stratum, which is reasonable due to  
7  
8 the randomisation of implant fitting. Patient ID will be included as a random effect to account  
9  
10 for the repeated measurements.

11  
12 Secondary outcomes will be analysed analogously in a constrained linear mixed model  
13  
14 adjusting for randomisation strata. Model validation checks will be undertaken as described  
15  
16 above, switching to bootstrapping the standard errors when model assumptions are rejected.  
17  
18

19  
20 Covariates such as age and gender will be included in all models.  
21  
22  
23  
24  
25

### 26 **Sensitivity analysis**

27  
28 Inclusion is performed conditional on Pure Tone Average (PTA) (from 0.5 to 4 kHz) PTA >  
29  
30 40 dB HL and SIS <50% in the ear considered for CI implantation and <70% in the best-aided  
31  
32 condition which may lead to a truncation effect in the distribution of baseline measurements.  
33  
34 To address this, an analysis of covariance (ANCOVA) model conditioning on the baseline will  
35  
36 be used to obtain a sensitivity analysis estimate for the main outcome. (2)  
37  
38

39  
40 The statistical analysis plan is attached as “supplementary file” along with the Data  
41  
42 Description listed in Appendix A.  
43  
44

45  
46 2)

47  
48 Liu, Guanghan F., Kaifeng Lu, Robin Mogg, Madhuj Mallick, and Devan V. Mehrotra. ‘Should  
49  
50 Baseline Be a Covariate or Dependent Variable in Analyses of Change from Baseline in  
51  
52 Clinical Trials?: ANALYSES OF CHANGE FROM BASELINE IN CLINICAL TRIALS’. *Statistics in*  
53  
54 *Medicine* 28, no. 20 (10 September 2009): 2509–30. <https://doi.org/10.1002/sim.3639>.  
55  
56  
57  
58  
59  
60





1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

# DATA DESCRIPTION

## APPENDIX A

Variable name	Content	Datatype	Missing	Excepted range (numeric data)
Inc_date	Date of inclusion	ddmmyy	No missing	

### Confounders

Age	Age at baseline	numeric	No missing	18-110
Sex		binary	No missing	
Medicine	Pupil-constricting/dilating	numeric	No missing	

### Before CI surgery

Variable name	Content	Datatype	Missing	Excepted range (numeric data)
<b>TRESHOLDS</b> Day 0 Baseline	The patient can be tested at frequencies from 125 Hz up to 8 kHz. Tresholds is tested with headphones and , each ear is tested separately, unaided. The masker is only added when there is a air bone gap >10dB at puretone audiometry	Numeric	Missing possible	0 to 120 db HL
<b>HINT</b> (word) Day 0 Baseline (One month with new replacement HA) Quiet HA right ear	Number of correct words or sentences out of 20 sentences with 5 words pr sentence. In free field. Speech level at 65dB HL.	Numeric	Missing possible	0-100%
<b>HINT</b> (word) Day 0 Baseline (One month with new replacement HA) Quiet HA left ear	Number of correct words or sentences out of 20 sentences with 5 words pr sentence In free field. Speech level at 65dB HL.	Numeric	Missing possible	0-100%

1 2 3 4 5 6 7 8 9 10	<b>HINT (word)</b> Day 0 Baseline (One month with new replacement HA) Quiet HA+HA	Number of correct words or sentences out of 20 sentences with 5 words pr sentence In free field. Speech level at 65dB HL.	Numeric	Missing possible	0-100%
11 12 13 14 15 16 17	<b>HINT (sentence)</b> Day 0 Baseline (One month with new replacement HA) Quiet HA right ear	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Missing possible	0-100%
18 19 20 21 22	<b>HINT (sentence)</b> Day 0 Baseline (One month with new replacement HA) Quiet HA left ear	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Missing possible	0-100%
23 24 25 26 27 28	<b>HINT (sentence)</b> Day 0 Baseline (One month with new replacement HA) Quiet HA+HA	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Missing possible	0-100%
29 30 31 32 33 34 35 36	<b>HINT (word)</b> Day 0 Baseline (One month with new replacement HA) Noise HA right ear	Number of correct words or sentences out of 20 sentences with 5 words pr sentence In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Missing possible	0-100%
37 38 39 40 41 42 43 44	<b>HINT (word)</b> Day 0 Baseline (One month with new replacement HA) Noise HA left ear	Number of correct words or sentences out of 20 sentences with 5 words pr sentence In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Missing possible	0-100%
45 46 47 48 49 50 51 52 53	<b>HINT (word)</b> Day 0 Baseline (One month with new replacement HA) Noise HA+HA	Number of correct words or sentences out of 20 sentences with 5 words pr sentence In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Missing possible	0-100%
54 55 56 57 58 59 60	<b>HINT (sentence)</b> Day 0 Baseline (One month with new replacement HA) Noise HA right ear	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted.	Numeric	Missing possible	0-100%

	Multi-talker babble noise.			
<b>HINT</b> (sentence) Day 0 Baseline (One month with new replacement HA) Noise HA left ear	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Missing possible	0-100%
<b>HINT</b> (sentence) Day 0 Baseline (One month with new replacement HA) Noise HA+HA	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Missing possible	0-100%
<b>SIS</b> free field Auditory Day 0 Baseline (One month with new replacement HA) Quiet HA+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Missing possible	0-100%
<b>SIS</b> free field Auditory Day 0 Baseline (One month with new replacement HA) Quiet HA left ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Missing possible	0-100%
<b>SIS</b> free field Auditory Day 0 Baseline (One month with new replacement HA) Noise HA+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Missing possible	0-100%
<b>SIS</b> free field Auditory Day 0 Baseline (One month with new replacement HA) Noise HA right ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Missing possible	0-100%
<b>SIS</b> free field Auditory Day 0 Baseline (One month with new replacement HA)	Speech identification score in Denmark is percentage correct words out of 25 words.	Numeric	Missing possible	0-100%

Noise HA left ear	Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.			
SIS free field Audio-visual Day 0 Baseline (One month with new replacement HA) Quiet HA+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Missing possible	0-100%
SIS free field Audio-visual Day 0 Baseline (One month with new replacement HA) Quiet HA right ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Missing possible	0-100%
SIS free field Audio-visual Day 0 Baseline (One month with new replacement HA) Quiet HA left ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Missing possible	0-100%
SIS free field Audio-visual Day 0 Baseline (One month with new replacement HA) Noise HA+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Missing possible	0-100%
SIS free field Audio-visual Day 0 Baseline (One month with new replacement HA) Noise HA right ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Missing possible	0-100%
SIS free field Audio-visual Day 0 Baseline (One month with new replacement HA) Noise HA left ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Missing possible	0-100%

	spectrum representing a real life "babble" noise.			
<b>Peak pupil dilation (PPD)</b> Day 0 Baseline (One month with new replacement HA) Quiet HA+HA	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at +10dB SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Missing possible	0-1
<b>Peak pupil dilation (PPD)</b> Day 0 Baseline (One month with new replacement HA) Noise HA+HA	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at +10dB SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Missing possible	0-1
<b>Pupil Peakttime</b> Day 0 Baseline (One month with new replacement HA) Quiet HA+HA	The time it takes for the pupil to reach peak dilation. HINT sentence presented at +10dB SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Missing possible	0-10sec
<b>Pupil Peakttime</b> Day 0 Baseline (One month with new replacement HA) Noise HA+HA	The time it takes for the pupil to reach peak dilation. HINT sentence presented at +10dB SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Missing possible	0-10sec
<b>NCIQ</b> Basic sound Day 0 Baseline (One month with new replacement HA)	Questionnaire	numeric	Missing possible	0-100
<b>NCIQ</b> Advanced Sound Day 0 Baseline (One month with new replacement HA)	Questionnaire	numeric	Missing possible	0-100

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	<p><b>NCIQ</b> Speech production Day 0 Baseline (One month with new replacement HA)</p>	Questionnaire	numeric	Missing possible	0-100
<p><b>NCIQ</b> Activity limitation Day 0 Baseline (One month with new replacement HA)</p>	Questionnaire	numeric	Missing possible	0-100	
<p><b>NCIQ</b> Social interaction Day 0 Baseline (One month with new replacement HA)</p>	Questionnaire	numeric	Missing possible	0-100	
<p><b>NCIQ</b> Total Day 0 Baseline (One month with new replacement HA)</p>	Questionnaire	numeric	Missing possible	0-100	
<p><b>SSQ</b> Speech intelligibility Day 0 Baseline (One month with new replacement HA)</p>	Questionnaire	numeric	Missing possible	0-100	
<p><b>SSQ</b> Spatial hearing Day 0 Baseline (One month with new replacement HA)</p>	Questionnaire	numeric	Missing possible	0-100	
<p><b>SSQ</b> Hearing quality Day 0 Baseline (One month with new replacement HA)</p>	Questionnaire	numeric	Missing possible	0-100	
<p><b>SSQ</b> Total Day 0 Baseline (One month with new replacement HA)</p>	Questionnaire	numeric	Missing possible	0-100	
<p><b>THI</b> Day 0 Baseline (One month with new replacement HA)</p>	Questionnaire	numeric	Missing possible	0-100	
<p><b>DHI</b> Day 0 Baseline (One month with new replacement HA)</p>	Questionnaire	numeric	Missing possible	0-100	
<p><b>HINT</b> (word) 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet HA right ear</p>	Number of correct words or sentences out of 20 sentences with 5 words pr sentence	Numeric	Missing possible	0-100%	
<p><b>HINT</b> (word) 3 months Follow-up with new HA</p>	Number of correct words or sentences out of 20 sentences	Numeric	Missing possible	0-100%	

(Total of 4 months with new replacement HA) Quiet HA left ear	with 5 words pr sentence			
<b>HINT (word)</b> 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet HA+HA	Number of correct words or sentences out of 20 sentences with 5 words pr sentence	Numeric	Missing possible	0-100%
<b>HINT (sentence)</b> 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet HA right ear	Number of correct sentences. (20 sentences in a HINT)	Numeric	Missing possible	0-100%
<b>HINT (sentence)</b> 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet HA left ear	Number of correct sentences. (20 sentences in a HINT)	Numeric	Missing possible	0-100%
<b>HINT (sentence)</b> 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet HA+HA	Number of correct sentences. (20 sentences in a HINT)	Numeric	Missing possible	0-100%
<b>HINT (word)</b> 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA right ear	Number of correct words or sentences out of 20 sentences with 5 words pr sentence	Numeric	Missing possible	0-100%
<b>HINT (word)</b> 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA left ear	Number of correct words or sentences out of 20 sentences with 5 words pr sentence	Numeric	Missing possible	0-100%
<b>HINT (word)</b> 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA+HA	Number of correct words or sentences out of 20 sentences with 5 words pr sentence	Numeric	Missing possible	0-100%
<b>HINT (sentence)</b> 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA right ear	Number of correct sentences. (20 sentences in a HINT)	Numeric	Missing possible	0-100%
<b>HINT (sentence)</b> 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA left ear	Number of correct sentences. (20 sentences in a HINT)	Numeric	Missing possible	0-100%
<b>HINT (sentence)</b> 3 months	Number of correct sentences.	Numeric	Missing possible	0-100%



Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA+HA	(20 sentences in a HINT)			
<b>SIS</b> free field Auditory 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet HA+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB.	Numeric	Missing possible	0-100%
<b>SIS</b> free field Auditory 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet HA right ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB.	Numeric	Missing possible	0-100%
<b>SIS</b> free field Auditory 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet HA left ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Missing possible	0-100%
<b>SIS</b> free field Auditory 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Missing possible	0-100%
<b>SIS</b> free field Auditory 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA right ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Missing possible	0-100%
<b>SIS</b> free field Auditory 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA left ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Missing possible	0-100%

1 2 3 4 5 6 7 8 9 10 11	<b>SIS</b> Headphones Auditory 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet	Speech identification score in Denmark is percentage correct words out of 25 words. Comfort speech level. Each ear is tested unaided separately.	Numeric	Missing possible	0-100%
12 13 14 15 16 17 18 19 20 21 22	<b>SIS</b> Headphones Auditory 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise	Speech identification score in Denmark is percentage correct words out of 25 words. Comfort speech level. Each ear is tested unaided separately. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life “babble” noise.	Numeric	Missing possible	0-100%
23 24 25 26 27 28	<b>SIS</b> free field Audio-visual 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet HA+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB .	Numeric	Missing possible	0-100%
29 30 31 32 33 34	<b>SIS</b> free field Audio-visual 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet HA right ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB .	Numeric	Missing possible	0-100%
35 36 37 38 39 40	<b>SIS</b> free field Audio-visual 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet HA left ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB .	Numeric	Missing possible	0-100%
41 42 43 44 45 46 47 48 49 50	<b>SIS</b> free field Audio-visual 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65db and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life “babble” noise.	Numeric	Missing possible	0-100%
51 52 53 54 55 56 57 58 59 60	<b>SIS</b> free field Audio-visual 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA right ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65db and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing	Numeric	Missing possible	0-100%

	a real life "babble" noise.			
<b>SIS free field</b> Audio-visual 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA left ear	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Missing possible	0-100%
<b>Peak pupil dilation (PPD)</b> 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet HA+HA	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Missing possible	0-1
<b>Peak pupil dilation (PPD)</b> 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA+HA	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Missing possible	0-1
<b>Pupil Peakttime</b> 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Quiet HA+HA	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Missing possible	0-10sec
<b>Pupil Peakttime</b> 3 months Follow-up with new HA (Total of 4 months with new replacement HA) Noise HA+HA	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses	Numeric	Missing possible	0-10sec

	Measurement & analysis tools			
<b>NCIQ</b> Basic sound 3 months Follow-up with new HA (Total of 4 months with new replacement HA)	Questionnaire	numeric	Missing possible	0-100
<b>NCIQ</b> Advanced Sound 3 months Follow-up with new HA (Total of 4 months with new replacement HA)	Questionnaire	numeric	Missing possible	0-100
<b>NCIQ</b> Speech production 3 months Follow-up with new HA (Total of 4 months with new replacement HA)	Questionnaire	numeric	Missing possible	0-100
<b>NCIQ</b> Self-esteem 3 months Follow-up with new HA (Total of 4 months with new replacement HA)	Questionnaire	numeric	Missing possible	0-100
<b>NCIQ</b> Activity limitation 3 months Follow-up with new HA (Total of 4 months with new replacement HA)	Questionnaire	numeric	Missing possible	0-100
<b>NCIQ</b> Social interaction 3 months Follow-up with new HA (Total of 4 months with new replacement HA)	Questionnaire	numeric	Missing possible	0-100
<b>NCIQ</b> Total 3 months Follow-up with new HA (Total of 4 months with new replacement HA)	Questionnaire	numeric	Missing possible	0-100
<b>SSQ</b> Spatial hearing 3 months Follow-up with new HA (Total of 4 months with new replacement HA)	Questionnaire	numeric	Missing possible	0-100
<b>SSQ</b> Hearing quality 3 months Follow-up with new HA (Total of 4 months with new replacement HA)	Questionnaire	numeric	Missing possible	0-100
<b>SSQ</b> Total 3 months Follow-up with new HA (Total of 4 months with new replacement HA)	Questionnaire	numeric	Missing possible	0-100
<b>THI</b> 3 months Follow-up with new HA (Total of 4 months with new replacement HA)	Questionnaire	numeric	Missing possible	0-100

<b>DHI</b> 3 months Follow-up with new HA (Total of 4 months with new replacement HA)	Questionnaire	Numeric	Missing possible	0-100
<b>After CI surgery</b>				
<b>Variable name</b>	<b>Content</b>	<b>Datatype</b>	<b>Missing</b>	<b>Excepted range (numeric data)</b>
<b>TRESHOLDS</b> CI activation day	The patient can be tested at frequencies from 125 Hz up to 8 kHz. Tresholds is tested with headphones and , each ear is tested separately, unaided. The masker is only added when there is a air bone gap >10dB at puretone audiometry	Numeric	Missing possible	0 to 120 db HL
<b>PTA</b> CI activation day	The patient can be tested at frequencies from 125 Hz up to 8 kHz. In free field. In best aided condition. No stimuli.	Numeric	Missing possible	0 to 120 db HL
<b>TRESHOLDS</b> 3 months post bimodal CI+HA-fitting	The patient can be tested at frequencies from 125 Hz up to 8 kHz. Tresholds is tested with headphones and , each ear is tested separately, unaided. The masker is only added when there is a air bone gap >10dB at puretone audiometry	Numeric	Missing possible	0 to 120 db HL
<b>PTA</b> 3 months post bimodal CI+HA - fitting	The patient can be tested at frequencies from 125 Hz up to 8 kHz. In free field. In best aided condition. No stimuli.	Numeric	Missing possible	0 to 120 db HL
<b>TRESHOLDS</b> 6 months post bimodal CI+HA - fitting	The patient can be tested at frequencies from 125 Hz up to 8 kHz.	Numeric	Missing possible	0 to 120 db HL

	Treshholds is tested with headphones and , each ear is tested separately, unaided. The masker is only added when there is a air bone gap >10dB at puretone audiometry			
<b>PTA</b> 6 months post bimodal CI+HA - fitting	The patient can be tested at frequencies from 125 Hz up to 8 kHz. In free field. In best aided condition. No stimuli.	Numeric	Missing possible	0 to 120 db HL
<b>TRESHOLDS</b> 12 months post bimodal CI+HA - fitting	The patient can be tested at frequencies from 125 Hz up to 8 kHz. Treshholds is tested with headphones and , each ear is tested separately, unaided. The masker is only added when there is a air bone gap >10dB at puretone audiometry	Numeric	Missing possible	0 to 120 db HL
<b>PTA</b> 12 months post bimodal CI+HA - fitting	The patient can be tested at frequencies from 125 Hz up to 8 kHz. In free field. In best aided condition. No stimuli.	Numeric	Missing possible	0 to 120 db HL
<b>HINT (word)</b> Post-surgery 3 months after fitting Quiet CI alone	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 6 months after fitting Quiet CI alone	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 12 months after fitting Quiet CI alone	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 3 months after fitting Quiet CI alone	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery	Number of correct sentences.	Numeric	Possible	0-100%

6 months after fitting Quiet CI alone	(20 sentences in a HINT) In free field. Speech level at 65dB HL.			
<b>HINT (sentence)</b> Post-surgery 12 month after fitting Quiet CI alone	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 3 months after fitting Quiet HA alone	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 6 months after fitting Quiet HA alone	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 12 months after fitting Quiet HA alone	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 3 months after fitting Quiet HA alone	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 6 months after fitting Quiet HA alone	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 12 months after fitting Quiet HA alone	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 3 months after fitting Quiet CI+HA	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 6 months after fitting Quiet CI+HA	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field.	Numeric	Possible	0-100%

	Speech level at 65dB HL.			
<b>HINT (word)</b> Post-surgery 12 months after fitting Quiet CI+HA	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 3 months after fitting Quiet CI+HA	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 6 months after fitting Quiet CI+HA	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 12 months after fitting Quiet CI+HA	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 3 months after fitting Noise CI alone	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 6 months after fitting Noise CI alone	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 12 months after fitting Noise CI alone	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 3 months after fitting Noise CI alone	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted.	Numeric	Possible	0-100%



	Multi-talker babble noise.			
<b>HINT (sentence)</b> Post-surgery 6 months after fitting Noise CI alone	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 12 months after fitting Noise CI alone	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 3 months after fitting Noise HA alone	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 6 months after fitting Noise HA alone	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 12 months after fitting Noise HA alone	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 3 months after fitting Noise HA alone	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 6 months after fitting Noise HA alone	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL.	Numeric	Possible	0-100%

	SNR +10 and adapted. Multi-talker babble noise.			
<b>HINT (sentence)</b> Post-surgery 12 months after fitting Noise HA alone	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 3 months after fitting Noise CI+HA	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 6 months after fitting Noise CI+HA	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (word)</b> Post-surgery 12 months after fitting Noise CI+HA	Number of correct words. (5 words per sentences, 20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 3 months after fitting Noise CI+HA	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 6 months after fitting Noise CI+HA	Number of correct sentences. (20 sentences in a HINT) In free field. Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.	Numeric	Possible	0-100%
<b>HINT (sentence)</b> Post-surgery 12 months after fitting Noise CI+HA	Number of correct sentences. (20 sentences in a HINT) In free field.	Numeric	Possible	0-100%

	Speech level at 65dB HL. SNR +10 and adapted. Multi-talker babble noise.			
SIS free field Auditory Post-surgery 3 months after fitting Noise CI only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Possible	0-100%
SIS free field Auditory Post-surgery 6 months after fitting Noise CI only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Possible	0-100%
SIS free field Auditory Post-surgery 12 months after fitting Noise CI only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Possible	0-100%
SIS free field Auditory Post-surgery 3 months after fitting Noise HA only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Possible	0-100%
SIS free field Auditory Post-surgery 6 months after fitting Noise HA only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Possible	0-100%

	a real life “babble” noise.			
SIS free field Auditory Post-surgery 12 months after fitting Noise HA only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life “babble” noise.	Numeric	Possible	0-100%
SIS free field Auditory Post-surgery 3 months after fitting Noise CI+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life “babble” noise.	Numeric	Possible	0-100%
SIS free field Auditory Post-surgery 6 months after fitting Noise CI+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life “babble” noise.	Numeric	Possible	0-100%
SIS free field Auditory Post-surgery 12 months after fitting Noise CI+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life “babble” noise.	Numeric	Possible	0-100%
SIS free field Auditory Post-surgery 3 months after fitting Quiet CI only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
SIS free field Auditory Post-surgery 6 months after fitting Quiet CI only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%

1 2 3 4 5 6 7 8	SIS free field Auditory Post-surgery 12 months after fitting Quiet CI only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
9 10 11 12 13	SIS free field Auditory Post-surgery 3 months after fitting Quiet HA only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
14 15 16 17 18	SIS free field Auditory Post-surgery 6 months after fitting Quiet HA only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
19 20 21 22	SIS free field Auditory Post-surgery 12 months after fitting Quiet HA only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
23 24 25 26 27	SIS free field Auditory Post-surgery 3 months after fitting Quiet CI+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
28 29 30 31 32	SIS free field Auditory Post-surgery 6 months after fitting Quiet CI+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
33 34 35 36	SIS free field Auditory Post-surgery 12 months after fitting Quiet CI+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
37 38 39 40 41	SIS free field Audio-visual Post-surgery 3 months after fitting Quiet CI+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
42 43 44 45	SIS free field Audio-visual Post-surgery 6 months after fitting Quiet CI+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
46 47 48 49 50	SIS free field Audio-visual Post-surgery 12 months after fitting Quiet CI+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
51 52 53 54	SIS free field Audio-visual Post-surgery 3 months after fitting Quiet CI only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
55 56 57 58 59	SIS free field Audio-visual Post-surgery 6 months after fitting Quiet CI only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%

1 2 3 4 5 6 7 8	SIS free field Audio-visual Post-surgery 12 months after fitting Quiet CI only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
9 10 11 12 13	SIS free field Audio-visual Post-surgery 3 months after fitting Quiet HA only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
14 15 16 17	SIS free field Audio-visual Post-surgery 6 months after fitting Quiet HA only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
18 19 20 21 22	SIS free field Audio-visual Post-surgery 12 months after fitting Quiet HA only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB	Numeric	Possible	0-100%
23 24 25 26 27 28 29 30 31 32	SIS free field Audio-visual Post-surgery 3 months after fitting Noise CI+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Possible	0-100%
33 34 35 36 37 38 39 40 41 42	SIS free field Audio-visual Post-surgery 6 months after fitting Noise CI+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Possible	0-100%
43 44 45 46 47 48 49 50 51 52	SIS free field Audio-visual Post-surgery 12 months after fitting Noise CI+HA	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Possible	0-100%
53 54 55 56 57 58 59 60	SIS free field Audio-visual Post-surgery 3 months after fitting Noise CI only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a	Numeric	Possible	0-100%

	speech shaped spectrum representing a real life "babble" noise.			
SIS free field Audio-visual Post-surgery 6 months after fitting Noise CI only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Possible	0-100%
SIS free field Audio-visual Post-surgery 12 months after fitting Noise CI only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Possible	0-100%
SIS free field Audio-visual Post-surgery 3 months after fitting Noise HA only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Possible	0-100%
SIS free field Audio-visual Post-surgery 6 months after fitting Noise HA only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Possible	0-100%
SIS free field Audio-visual Post-surgery 12 months after fitting Noise HA only	Speech identification score in Denmark is percentage correct words out of 25 words. Speech level is 65dB and noise level is 65dB. The noise signal is amplitude modulated and has a speech shaped spectrum representing a real life "babble" noise.	Numeric	Possible	0-100%
Peak pupil dilation (PPD) Post-surgery	PPD is calculated based on the number of pixels. PPD of 0.01	Numeric	Possible	0-1

3 months after fitting Quiet CI only	would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools			
<b>Peak pupil dilation (PPD)</b> Post-surgery 6 months after fitting Quiet CI only	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-1
<b>Peak pupil dilation (PPD)</b> Post-surgery 12 months after fitting Quiet CI only	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-1
<b>Peak pupil dilation (PPD)</b> Post-surgery 3 months after fitting Quiet HA only	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-1
<b>Peak pupil dilation (PPD)</b> Post-surgery 6 months after fitting Quiet HA only	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive	Numeric	Possible	0-1



	SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools			
<b>Peak pupil dilation (PPD)</b> Post-surgery 12 months after fitting Quiet HA only	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-1
<b>Peak pupil dilation (PPD)</b> Post-surgery 3 months after fitting Quiet CI+HA	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-1
<b>Peak pupil dilation (PPD)</b> Post-surgery 6 months after fitting Quiet CI+HA	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-1
<b>Peak pupil dilation (PPD)</b> Post-surgery 12 months after fitting Quiet CI+HA	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-1
<b>Peak pupil dilation (PPD)</b>	PPD is calculated based on the number	Numeric	Possible	0-1

<p>Post-surgery 3 months after fitting Noise CI only</p>	<p>of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement &amp; analysis tools</p>			
<p><b>Peak pupil dilation (PPD)</b> Post-surgery 6 months after fitting Noise CI only</p>	<p>PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement &amp; analysis tools</p>	<p>Numeric</p>	<p>Possible</p>	<p>0-1</p>
<p><b>Peak pupil dilation (PPD)</b> Post-surgery 12 months after fitting Noise CI only</p>	<p>PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement &amp; analysis tools</p>	<p>Numeric</p>	<p>Possible</p>	<p>0-1</p>
<p><b>Peak pupil dilation (PPD)</b> Post-surgery 3 months after fitting Noise HA only</p>	<p>PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement &amp; analysis tools</p>	<p>Numeric</p>	<p>Possible</p>	<p>0-1</p>
<p><b>Peak pupil dilation (PPD)</b> Post-surgery 6 months after fitting Noise HA only</p>	<p>PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive</p>	<p>Numeric</p>	<p>Possible</p>	<p>0-1</p>

	SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools			
<b>Peak pupil dilation (PPD)</b> Post-surgery 12 months after fitting Noise HA only	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-1
<b>Peak pupil dilation (PPD)</b> Post-surgery 3 months after fitting Noise CI+HA	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-1
<b>Peak pupil dilation (PPD)</b> Post-surgery 6 months after fitting Noise CI+HA	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-1
<b>Peak pupil dilation (PPD)</b> Post-surgery 12 months after fitting Noise CI+HA	PPD is calculated based on the number of pixels. PPD of 0.01 would mean 1% change in pupil dilation. HINT sentence presented at speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-1

<p><b>Pupil Peaktime</b> Post-surgery 3 months after fitting Quiet CI only</p>	<p>The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement &amp; analysis tools</p>	<p>Numeric</p>	<p>Possible</p>	<p>0-10sec</p>
<p><b>Pupil Peaktime</b> Post-surgery 6 months after fitting Quiet CI only</p>	<p>The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement &amp; analysis tools</p>	<p>Numeric</p>	<p>Possible</p>	<p>0-10sec</p>
<p><b>Pupil Peaktime</b> Post-surgery 12 months after fitting Quiet CI only</p>	<p>The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement &amp; analysis tools</p>	<p>Numeric</p>	<p>Possible</p>	<p>0-10sec</p>
<p><b>Pupil Peaktime</b> Post-surgery 3 months after fitting Quiet HA only</p>	<p>The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement &amp; analysis tools</p>	<p>Numeric</p>	<p>Possible</p>	<p>0-10sec</p>
<p><b>Pupil Peaktime</b> Post-surgery 6 months after fitting Quiet HA only</p>	<p>The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement &amp; analysis tools</p>	<p>Numeric</p>	<p>Possible</p>	<p>0-10sec</p>
<p><b>Pupil Peaktime</b> Post-surgery 12 months after fitting Quiet HA only</p>	<p>The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at</p>	<p>Numeric</p>	<p>Possible</p>	<p>0-10sec</p>

	+10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools			
<b>Pupil Peaktime</b> Post-surgery 3 months after fitting Quiet CI+HA	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-10sec
<b>Pupil Peaktime</b> Post-surgery 6 months after fitting Quiet CI+HA	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-10sec
<b>Pupil Peaktime</b> Post-surgery 12 months after fitting Quiet CI+HA	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-10sec
<b>Pupil Peaktime</b> Post-surgery 3 months after fitting Noise CI only	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-10sec
<b>Pupil Peaktime</b> Post-surgery 6 months after fitting Noise CI only	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-10sec

1 2 3 4 5 6 7 8 9 10 11 12 13 14	<b>Pupil Peaktime</b> Post-surgery 12 months after fitting Noise CI only	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-10sec
15 16 17 18 19 20 21 22 23 24	<b>Pupil Peaktime</b> Post-surgery 3 months after fitting Noise HA only	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-10sec
25 26 27 28 29 30 31 32 33 34	<b>Pupil Peaktime</b> Post-surgery 6 months after fitting Noise HA only	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-10sec
35 36 37 38 39 40 41 42 43 44	<b>Pupil Peaktime</b> Post-surgery 12 months after fitting Noise HA only	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-10sec
45 46 47 48 49 50 51 52 53 54	<b>Pupil Peaktime</b> Post-surgery 3 months after fitting Noise CI+HA	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-10sec
55 56 57 58 59 60	<b>Pupil Peaktime</b> Post-surgery 6 months after fitting Noise CI+HA	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive	Numeric	Possible	0-10sec

	SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools			
<b>Pupil Peaktme</b> Post-surgery 12 months after fitting Noise CI+HA	The time it takes for the pupil to reach peak dilation. HINT sentence presented speech level 65dB and SNR at +10dB and adaptive SNR, multi-talker babble noise Oticon Medical Pupil Labs glasses Measurement & analysis tools	Numeric	Possible	0-10sec
<b>NCIQ</b> Basic sound Post-surgery 3 months after fitting	Questionnaire	numeric	Possible	0-100
<b>NCIQ</b> Advanced Sound Post-surgery 3 months after fitting	Questionnaire	numeric	Possible	0-100
<b>NCIQ</b> Speech production Post-surgery 3 months after fitting	Questionnaire	numeric	Possible	0-100
<b>NCIQ</b> Self-esteem Post-surgery 3 months after fitting	Questionnaire	numeric	Possible	0-100
<b>NCIQ</b> Activity limitation Post-surgery 3 months after fitting	Questionnaire	numeric	Possible	0-100
<b>NCIQ</b> Social interaction Post-surgery 3 months after fitting	Questionnaire	numeric	Possible	0-100
<b>NCIQ</b> Total Post-surgery 3 months after fitting	Questionnaire	numeric	Possible	0-100
<b>NCIQ</b> Basic sound Post-surgery 6 months after fitting	Questionnaire	numeric	Possible	0-100
<b>NCIQ</b> Advanced Sound Post-surgery 6 months after fitting	Questionnaire	numeric	Possible	0-100
<b>NCIQ</b> Speech production Post-surgery 6 months after fitting	Questionnaire	numeric	Possible	0-100
<b>NCIQ</b> Self-esteem Post-surgery 6 months after fitting	Questionnaire	numeric	Possible	0-100
<b>NCIQ</b> Activity limitation Post-surgery 6 months after fitting	Questionnaire	numeric	Possible	0-100
<b>NCIQ</b> Social interaction Post-surgery 6 months after fitting	Questionnaire	numeric	Possible	0-100





12 months after fitting				
<b>SSQ</b> Hearing quality Post-surgery 12 months after fitting	Questionnaire	numeric	Possible	0-100
<b>SSQ</b> Total Post-surgery 12 months after fitting	Questionnaire	numeric	Possible	0-100
<b>THI</b> Post-surgery 2 weeks before fitting	Questionnaire	numeric	Possible	0-100
<b>THI</b> Post-surgery 3 months after fitting	Questionnaire	numeric	Possible	0-100
<b>THI</b> Post-surgery 6 months after fitting	Questionnaire	numeric	Possible	0-100
<b>THI</b> Post-surgery 12 months after fitting	Questionnaire	numeric	Possible	0-100
<b>DHI</b> Post-surgery 2 weeks before fitting	Questionnaire	numeric	Possible	0-100
<b>DHI</b> Post-surgery 3 months after fitting	Questionnaire	numeric	Possible	0-100
<b>DHI</b> Post-surgery 6 months after fitting	Questionnaire	numeric	Possible	0-100
<b>DHI</b> Post-surgery 12 months after fitting	Questionnaire	numeric	Possible	0-100



# CONSORT 2010 checklist of information to include when reporting a randomised trial\*

Section/Topic	Item No	Checklist item	Reported on page No
<b>Title and abstract</b>			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	1
<b>Introduction</b>			
Background and objectives	2a	Scientific background and explanation of rationale	3-6
	2b	Specific objectives or hypotheses	5-6
<b>Methods</b>			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	6-10
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	10-12
Participants	4a	Eligibility criteria for participants	10-12
	4b	Settings and locations where the data were collected	
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	12-13
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	13
	6b	Any changes to trial outcomes after the trial commenced, with reasons	
Sample size	7a	How sample size was determined	
	7b	When applicable, explanation of any interim analyses and stopping guidelines	13-15
<b>Randomisation:</b>			
Sequence generation	8a	Method used to generate the random allocation sequence	9-10
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	9-10
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	9-10/14-15
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	

bmjopen-2022-070296 on 29 December 2022. Downloaded from <http://bmjopen.bmj.com/> on April 27, 2024 by guest. Protected by copyright.

1		assessing outcomes) and how	
2	11b	If relevant, description of the similarity of interventions	14-15
3	Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes
4		12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses
5			
6	<b>Results</b>		
7	Participant flow (a	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and
8	diagram is strongly		were analysed for the primary outcome
9	recommended)	13b	For each group, losses and exclusions after randomisation, together with reasons
10	Recruitment	14a	Dates defining the periods of recruitment and follow-up
11		14b	Why the trial ended or was stopped
12	Baseline data	15	A table showing baseline demographic and clinical characteristics for each group
13	Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was
14			by original assigned groups
15	Outcomes and	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its
16	estimation		precision (such as 95% confidence interval)
17		17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended
18	Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing
19			pre-specified from exploratory
20	Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)
21	<b>Discussion</b>		
22	Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses
23	Generalisability	21	Generalisability (external validity, applicability) of the trial findings
24	Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence
25	<b>Other information</b>		
26	Registration	23	Registration number and name of trial registry
27	Protocol	24	Where the full trial protocol can be accessed, if available
28	Funding	25	Sources of funding and other support (such as supply of drugs), role of funders
29			1, 2, 16, 17
30			17

36  
37 \*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also  
38 recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials.  
39 Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).  
40  
41  
42



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist for the ReTrain pilot RCT: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	2,7,17
	2b	All items from the World Health Organization Trial Registration Data Set	Yes, clinicaltrials.org
Protocol version	3	Date and version identifier	1
Funding	4	Sources and types of financial, material, and other support	17
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1,17
	5b	Name and contact information for the trial sponsor	1,17
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	17
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	17

bmjopen-2022-070296 on 29 December 2022. Downloaded from <http://bmjopen.bmj.com/> on April 27, 2024 by guest. Protected by copyright.

1	<b>Introduction</b>			
2				
3	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	3-6
4				
5				
6		6b	Explanation for choice of comparators	4-5
7				
8	Objectives	7	Specific objectives or hypotheses	6
9				
10	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	7
11				
12				
13				
14	<b>Methods: Participants, interventions, and outcomes</b>			
15				
16	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	1,7,9,10
17				
18				
19	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	7-8
20				
21				
22	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	8-13
23				
24				
25				
26		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	11
27				
28				
29		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	11-12
30				
31				
32		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	12
33				
34	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	9-10,13-15, Appendix A
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	8-9,11-13 Appendix A, Figure 1 and 2
5	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	14, Table 1
8	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	7-10

### Methods: Assignment of interventions (for controlled trials)

#### Allocation:

15	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	9-10
21	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	9-10
25	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	9-10
28	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	9-10
32		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	9-10

### Methods: Data collection, management, and analysis

37	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	13-15, statistical plan(SAP), Data management plan(DMP)
----	-------------------------	-----	--	--

1		18b	Plans to promote participant retention and complete follow-up, including list of any outcomes data to be collected for participants who discontinue or deviate from intervention protocols	13-15, SAP, DMP,
2				
3				
4	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	13-15, SAP, DMP, Appendix A
5				
6				
7				
8	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	13-15, SAP
9				
10				
11		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	13-15, SAP
12				
13		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	13-15, SAP
14				
15				
16				
17	<b>Methods: Monitoring</b>			
18				
19	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	17
20				
21				
22				
23				
24				
25		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	n/a
26				
27				
28	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	13-15, SAP
29				
30				
31	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	n/a
32				
33				
34				
35	<b>Ethics and dissemination</b>			
36				
37	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	2,7,16
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	13-15, SAP
5	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	2,9,11,16
8		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	n/a
11	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	2,9,11,16
15	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	17
18	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	17,MAP
21	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	Consent form
24	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, health care professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	17
29		31b	Authorship eligibility guidelines and any intended use of professional writers	17
31		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	MAP
33	<b>Appendices</b>			
35	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	As online supplementary file
38	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

For peer review only